[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1503
1. Hassan R, White LR, Stefanoff CG, de Oliveira DE, Felisbino FE, Klumb CE, Bacchi CE, Seuánez HN, Zalcberg IR: Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol; 2006 Aug 07;1:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a systematic comparison between RISH and PCR for EBV detection, in a group of childhood B-cell Non-Hodgkin lymphomas (NHL), aiming to validate PCR as a first, rapid method for the diagnosis of EBV-associated B-cell NHL.
  • METHODS: EBV infection was investigated in formalin fixed paraffin-embedded tumor samples of 41 children with B-cell NHL, including 35 Burkitt's lymphoma (BL), from Rio de Janeiro, Brazil, by in situ hybridization of EBV-encoded small RNA (EBER-RISH) and PCR assays based on EBNA2 amplification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1992 Aug;141(2):457-65 [1323222.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1572-5 [15284857.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] Cell. 1988 Jan 15;52(1):51-61 [2830981.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] J Virol. 1994 Nov;68(11):7374-85 [7933121.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):604-11 [7967515.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):239-52 [8053485.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Pediatr Pathol. 1994 Jan-Feb;14(1):101-9 [8159607.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):36-42 [8381202.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1045-55 [8562929.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] J Virol. 1996 May;70(5):3286-9 [8627812.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1245-52 [8630905.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3949-55 [10339504.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):79-87 [12766612.001]
  • [Cites] J Clin Microbiol. 1999 Sep;37(9):2852-7 [10449464.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):331-5 [11860309.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):329-37 [11342313.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Apr;34(1):27-53 [10781747.001]
  • [Cites] Arch Pathol Lab Med. 1999 Nov;123(11):1098-100 [10539915.001]
  • (PMID = 16893464.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082274
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1559641
  •  go-up   go-down


2. Cazzaniga G, Biondi A: Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica; 2005 Mar;90(3):382-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
  • The use of minimal residual disease (MRD) measurement as a surrogate marker of molecular response to treatment can potentially improve the evaluation of treatment response and enable estimates of the residual leukemic cell burden during clinical remission, thereby improving the selection of therapeutic strategies and, possibly, long-term clinical outcome.
  • Several retrospective studies have demonstrated the strong association between MRD and risk of relapse in childhood acute lymphoid leukemia (ALL), irrespective of the methodology used.
  • [MeSH-major] Gene Rearrangement. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749670.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunoglobulin G
  • [Number-of-references] 55
  •  go-up   go-down


3. Yang Y, Takeuchi S, Hofmann WK, Ikezoe T, van Dongen JJ, Szczepański T, Bartram CR, Yoshino N, Taguchi H, Koeffler HP: Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk Res; 2006 Jan;30(1):98-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia.
  • Methylation profile was analyzed in 10 childhood acute lymphoblastic leukemia (ALL) and nine adult ALL cases.
  • Methylation of the RARbeta was more frequent in adult ALL than that in childhood ALL (p=0.01).
  • The number of patients with methylation of multiple genes was higher in adult ALL than that in childhood ALL (p=0.006).
  • Moreover, overall frequency of methylation was higher in adult ALL than that in childhood ALL (p=0.01).
  • [MeSH-major] CpG Islands. DNA Methylation. Neoplasm Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism


Advertisement
4. Carey ME, Haut MW, Reminger SL, Hutter JJ, Theilmann R, Kaemingk KL: Reduced frontal white matter volume in long-term childhood leukemia survivors: a voxel-based morphometry study. AJNR Am J Neuroradiol; 2008 Apr;29(4):792-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced frontal white matter volume in long-term childhood leukemia survivors: a voxel-based morphometry study.
  • BACKGROUND AND PURPOSE: To our knowledge, no published studies have examined whole-brain regional differences to identify more discrete volumetric changes in the brains of childhood leukemia survivors.
  • We used voxel-based morphometry (VBM) to examine regional gray and white matter differences in a group of long-term survivors of acute lymphoblastic leukemia (ALL) compared with a group of healthy controls.
  • [MeSH-major] Frontal Lobe / pathology. Magnetic Resonance Imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Survivors

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184841.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINR NIH HHS / NR / P20 NR07794; United States / NICHD NIH HHS / HD / R01 HD37816
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


5. MacKenzie J, Greaves MF, Eden TO, Clayton RA, Perry J, Wilson KS, Jarrett RF: The putative role of transforming viruses in childhood acute lymphoblastic leukemia. Haematologica; 2006 Feb;91(2):240-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The putative role of transforming viruses in childhood acute lymphoblastic leukemia.
  • Epidemiological evidence suggests that infection is involved in the etiology of common acute lymphoblastic leukemia, either by stimulating an inappropriate immune response or in the form of a classical transforming agent.
  • These results suggest that it is unlikely that a single, direct transforming agent is involved in the pathogenesis of common acute lymphoblastic leukemia.
  • [MeSH-major] Cell Transformation, Viral. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology


6. Lemez P, Attarbaschi A, Béné MC, Bertrand Y, Castoldi G, Forestier E, Garand R, Haas OA, Kagialis-Girard S, Ludwig WD, Matutes E, Mejstríková E, Pages MP, Pickl W, Porwit A, Orfao A, Schabath R, Starý J, Strobl H, Talmant P, van't Veer MB, Zemanová Z, European Group for the Immunological Characterization of Leukemias (EGIL): Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases. Eur J Haematol; 2010 Oct;85(4):300-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases.
  • OBJECTIVES: Patients with near-tetraploid (karyotype: 81 - 103 chromosomes) acute lymphoblastic leukemia (NT-ALL) constitute about 1% of childhood ALL and data reported on them are limited and controversial.
  • Ten children were diagnosed as T-cell ALL (T-ALL) EGIL categories (T-I n=2, T-II n=2, T-III n=3, T-IV n=3) and four displayed various structural chromosomal abnormalities.
  • B-cell precursor (BCP) ALL was diagnosed in 26 children.
  • One girl with hypodiploid and NT metaphases and ETV6-RUNX1-negative BCP-ALL and one of two boys with NT-BCP-ALL not examined for ETV6-RUNX1 died of infection after stem cell transplantation in 2nd/3rd CR.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20561032.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


7. Balduzzi A, De Lorenzo P, Schrauder A, Conter V, Uderzo C, Peters C, Klingebiel T, Stary J, Felice MS, Magyarosy E, Schrappe M, Dini G, Gadner H, Valsecchi MG: Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica; 2008 Jun;93(6):925-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time.
  • The advantage of allogeneic transplant from compatible related donors versus chemotherapy in children with very-high-risk acute lymphoblastic leukemia in first complete remission was previously demonstrated in an international prospective trial.
  • Of 357 pediatric patients with very-high-risk acute lymphoblastic leukemia, 259 received chemotherapy, 55 transplantation from compatible related and 43 from unrelated donors.
  • The relative advantage of transplant from compatible related donors in very-high-risk childhood acute lymphoblastic leukemia was consistent for any time elapsed in first remission.
  • [MeSH-major] Bone Marrow Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / methods


8. Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, Thithapandha A, Hongeng S: Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Jan;48(1):16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia.
  • This study was performed to evaluate the effect of the polymorphisms of DNA repair genes on risk of childhood acute lymphoblastic leukemia (ALL).
  • CONCLUSION: The XRCC1 194Trp allele and haplotype B showed a protective effect against development of childhood ALL.
  • [MeSH-major] Alleles. DNA Repair. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16435384.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1
  •  go-up   go-down


9. Strefford JC, Worley H, Barber K, Wright S, Stewart AR, Robinson HM, Bettney G, van Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, Saha V, Moorman AV, Harrison CJ: Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene; 2007 Jun 21;26(29):4306-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization.
  • Chromosomal abnormalities are important for the classification and risk stratification of patients with acute lymphoblastic leukemia (ALL).
  • However, approximately 30% of childhood and 50% of adult patients lack abnormalities with clinical relevance.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Profiling. Genome, Human. Leukemia-Lymphoma, Adult T-Cell / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237825.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Williams S, MacDonald P, Hoyer JD, Barr RD, Athale UH: Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatr Blood Cancer; 2005 Jan;44(1):55-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels.
  • Methemoglobinemia is a known complication of dapsone, but its true frequency and pathogenesis in childhood cancer patients are unknown.
  • PROCEDURE: We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels.
  • [MeSH-major] Anti-Infective Agents / adverse effects. Anti-Infective Agents / therapeutic use. Cytochrome-B(5) Reductase / pharmacology. Dapsone / adverse effects. Dapsone / therapeutic use. Methemoglobinemia / chemically induced. Methemoglobinemia / prevention & control. Pneumonia, Pneumocystis / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAPSONE .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15390276.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 8W5C518302 / Dapsone; EC 1.6.2.2 / Cytochrome-B(5) Reductase
  •  go-up   go-down


11. Andersson A, Olofsson T, Lindgren D, Nilsson B, Ritz C, Edén P, Lassen C, Råde J, Fontes M, Mörse H, Heldrup J, Behrendtz M, Mitelman F, Höglund M, Johansson B, Fioretos T: Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci U S A; 2005 Dec 27;102(52):19069-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations.
  • Global expression profiles of a consecutive series of 121 childhood acute leukemias (87 B lineage acute lymphoblastic leukemias, 11 T cell acute lymphoblastic leukemias, and 23 acute myeloid leukemias), six normal bone marrows, and 10 normal hematopoietic subpopulations of different lineages and maturations were ascertained by using 27K cDNA microarrays.
  • By applying the three principal components obtained from PCA of the normal cells on the leukemic samples, similarities between malignant and normal cell lineages and maturations were investigated.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia / genetics
  • [MeSH-minor] Bone Marrow / metabolism. Bone Marrow Cells / cytology. Cell Line. Cell Lineage. Chromosome Aberrations. Cluster Analysis. DNA, Complementary / metabolism. Gene Expression Regulation. Genes, Neoplasm. Hematopoiesis. Hematopoietic Stem Cells / cytology. Hematopoietic System / metabolism. Humans. Leukemia, Myeloid, Acute / genetics. Models, Genetic. Myeloid-Lymphoid Leukemia Protein. Oligonucleotide Array Sequence Analysis. Ploidies. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Principal Component Analysis. Transcription Factors / chemistry


12. Barakat M, Elkhayat Z, Kholoussi N, Elnady H, Ismail M, Raafat J: Monitoring treatment response of childhood acute lymphocytic leukemia with certain molecular and biochemical markers. J Biochem Mol Toxicol; 2010 Nov-Dec;24(6):343-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring treatment response of childhood acute lymphocytic leukemia with certain molecular and biochemical markers.
  • Apoptosis is the primary mechanism through which most chemotherapeutic agents induce tumor cell death.
  • The purpose of this study was to monitor the expression of pro- and anti-apoptotic proteins CD(95) , Bcl-2, as well as copper and zinc levels in the peripheral blood of children with acute lymphocytic leukemia (ALL) prior to and 6 months after the beginning of chemotherapy.
  • [MeSH-major] Apoptosis. Apoptosis Regulatory Proteins / blood. Biomarkers. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley Periodicals, Inc.
  • (PMID = 21182165.001).
  • [ISSN] 1099-0461
  • [Journal-full-title] Journal of biochemical and molecular toxicology
  • [ISO-abbreviation] J. Biochem. Mol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers; 0 / Proto-Oncogene Proteins c-bcl-2; 789U1901C5 / Copper; J41CSQ7QDS / Zinc
  •  go-up   go-down


13. Tsuchida M, Ohara A, Manabe A, Kumagai M, Shimada H, Kikuchi A, Mori T, Saito M, Akiyama M, Fukushima T, Koike K, Shiobara M, Ogawa C, Kanazawa T, Noguchi Y, Oota S, Okimoto Y, Yabe H, Kajiwara M, Tomizawa D, Ko K, Sugita K, Kaneko T, Maeda M, Inukai T, Goto H, Takahashi H, Isoyama K, Hayashi Y, Hosoya R, Hanada R, Tokyo Children's Cancer Study Group: Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia; 2010 Feb;24(2):383-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999.
  • We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033052.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Kigasawa H; Hashiyama M; Migita M; Matsui A; Yoshihawa H; Kawaguchi H; Makimoto A; Hosono A; Takagi K; Morinaga S; Kiyotani C; Shiota Y; Moriwaki K; Mochizuki S; Toyama D; Kato Y; Hoshi Y; Gunji Y; Kashii Y; Morimoto T; Saito M; Fujimura J; Ishimoto K; Isoyama K; Yamamoto M; Hirota T; Koike K; Yanagisawa R; Ishii E; Kinoshita A; Kondo K; Morimoto M; Ishida Y; Ozawa M; Hasegawa D; Kamiya T; Ochiai H; Sato Y; Sakao E; Ito K; Sunami K; Igarashi T; Komori I; Kakuta H; Kato S; Morimoto K; Yabe M; Mizutani S; Nagasawa M; Koana S; Kashiwagi Y; Takita J; Kato KM; Ooki K; Wada E; Kato F; Kojima Y; Mitsui K; Uchino Y; Watanabe A; Fukushima K; Kurosawa H; Hagisawa S; Sato Y; Fukuoka K; Sugita M; Kaku H; Kawamura M; Fukunaga Y; Migita S; Ueda T; Asano K; Sugita K; Goi K; Fugii H; Ikuta K; Yanagimachi M; Yokosuka T; Kai S; Goto A; Tanaka F; Tsuji K; Ebihara Y; Nakadate N; Ishiguro Y; Suzuki T; Nakao S; Sotomatsu M; Paku A; Bessho F; Yoshino H; Ishii M; Genma Y; Kogawa K; Tsuji Y; Imai K; Sawa F
  •  go-up   go-down


14. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A: Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood; 2009 Apr 2;113(14):3287-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD133 on leukemia-initiating cells in childhood ALL.
  • Optimization of therapy for childhood acute lymphoblastic leukemia (ALL) requires a greater understanding of the cells that proliferate to maintain this malignancy because a significant number of cases relapse, resulting from failure to eradicate the disease.
  • We investigated expression of CD133, CD19, and CD38 in pediatric B-ALL.
  • Furthermore, these CD133(+)/CD19(-) ALL cells were more resistant to treatment with dexamethasone and vincristine, key components in childhood ALL therapy, than the bulk leukemia population.
  • These data suggest that leukemia-initiating cells in childhood B-ALL have a primitive CD133(+)/CD19(-) and CD38(-) phenotype.
  • [MeSH-major] Antigens, CD / metabolism. Glycoproteins / metabolism. Neoplastic Stem Cells / metabolism. Peptides / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Animals. Antigens, CD19 / metabolism. Antigens, CD38 / metabolism. Cell Proliferation. Child. Child, Preschool. Gene Rearrangement, T-Lymphocyte / physiology. Humans. Immunoglobulin Heavy Chains / genetics. Membrane Glycoproteins / metabolism. Mice. Mice, Inbred NOD. Mice, SCID. Phenotype. Transplantation, Heterologous. Tumor Cells, Cultured

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2009 Apr 30;113(18):4476-7; author reply 4477 [19407001.001]
  • (PMID = 19147788.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Glycoproteins; 0 / Immunoglobulin Heavy Chains; 0 / Membrane Glycoproteins; 0 / Peptides; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


15. von Goessel H, Jacobs U, Semper S, Krumbholz M, Langer T, Keller T, Schrauder A, van der Velden VH, van Dongen JJ, Harbott J, Panzer-Grümayer ER, Schrappe M, Rascher W, Metzler M: Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia. Leuk Res; 2009 Aug;33(8):1082-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia.
  • Fusion between ETV6 and RUNX1 defines the largest genetic subgroup in childhood ALL.
  • [MeSH-major] Biomarkers, Tumor / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081626.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


16. Zuna J, Cavé H, Eckert C, Szczepanski T, Meyer C, Mejstrikova E, Fronkova E, Muzikova K, Clappier E, Mendelova D, Boutard P, Schrauder A, Sterba J, Marschalek R, van Dongen JJ, Hrusak O, Stary J, Trka J: Childhood secondary ALL after ALL treatment. Leukemia; 2007 Jul;21(7):1431-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood secondary ALL after ALL treatment.
  • Data on secondary acute lymphoblastic leukaemia (sALL) following ALL treatment are very rare.
  • Examination of immunoglobulin and T-cell receptor gene rearrangements brought a new tool that can help in discrimination between relapse and sALL.
  • We focused on the recurrences of childhood ALL to discover the real frequency of the sALL after ALL treatment.
  • [MeSH-major] Molecular Diagnostic Techniques / methods. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460701.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Stanulla M, Schaeffeler E, Möricke A, Coulthard SA, Cario G, Schrauder A, Kaatsch P, Dördelmann M, Welte K, Zimmermann M, Reiter A, Eichelbaum M, Riehm H, Schrappe M, Schwab M: Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. Blood; 2009 Aug 13;114(7):1314-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
  • Treatment for childhood acute lymphoblastic leukemia (ALL) regularly includes the use of thiopurine drugs.
  • Importantly, childhood ALL patients with low TPMT activity have been considered to be at increased risk of developing therapy-associated acute myeloid leukemia and brain tumors.
  • Thus, TPMT does not play a major role in the etiology of secondary malignant neoplasm after treatment for childhood ALL, according to Berlin-Frankfurt-Münster strategies.
  • [MeSH-major] Brain Neoplasms / genetics. Leukemia, Myeloid, Acute / enzymology. Methyltransferases / genetics. Neoplasms, Second Primary / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


18. Gutiérrez MI, Timson G, Siraj AK, Bu R, Barbhaya S, Banavali S, Bhatia K: Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts. J Mol Diagn; 2005 Feb;7(1):40-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • t(9;22) generates the BCR-ABL fusion gene, the hallmark of chronic myeloid leukemia (CML) but also found in acute lymphoblastic leukemia (ALL).
  • We applied this assay to assess the distribution of p190 and p210 in 260 childhood ALL samples from India.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Nov;13(11):1825-32 [10557058.001]
  • [Cites] Haematologica. 2003 Sep;88(9):1074-6 [12969819.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Haematologica. 2000 Dec;85(12):1248-54 [11114130.001]
  • [Cites] Haematologica. 2001 Mar;86(3):252-9 [11255271.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Leukemia. 2002 Jan;16(1):53-9 [11840263.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Med Sci Monit. 2002 May;8(5):BR193-7 [12011769.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1167-75 [12040449.001]
  • [Cites] Ann Oncol. 2002 May;13(5):781-8 [12075749.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):445-53 [12406084.001]
  • [Cites] Am J Hematol. 2002 Dec;71(4):291-9 [12447959.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1423-32 [14534335.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:132-52 [14633780.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):96-103 [14657955.001]
  • [Cites] N Engl J Med. 1988 Oct 13;319(15):990-8 [3047582.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1819-24 [2224129.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2411-8 [1932753.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4603-11 [8541551.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5213-7 [8652835.001]
  • [Cites] Leukemia. 1996 Jun;10(6):957-63 [8667652.001]
  • [Cites] Baillieres Clin Haematol. 1997 Jun;10(2):203-22 [9376660.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3171-4 [10397261.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3832-40 [12473597.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Mar;36(3):211-23 [12557221.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1033-41 [12569603.001]
  • [Cites] Eur J Haematol. 2003 Jan;70(1):1-10 [12631253.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):63-72 [12707370.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1192-3 [12764391.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):42-8 [12866371.001]
  • [Cites] Curr Oncol Rep. 2003 Sep;5(5):426-35 [12895396.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • (PMID = 15681473.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC1867499
  •  go-up   go-down


19. Campana D: Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 2009 Oct;23(5):1083-98, vii
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.
  • Assays that measure minimal residual disease (MRD) can determine the response to treatment in patients with acute lymphoblastic leukemia (ALL) much more precisely than morphologic screening of bone marrow smears.
  • The clinical significance of MRD, detected by flow cytometry or polymerase chain reaction-based methods in childhood ALL, has been established.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3046-50 [18565891.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:366-73 [19074112.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2193-200 [18754029.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):100-6 [19100372.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4153-62 [19141862.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1073-9 [19212338.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3533-9 [19546402.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):227-37 [18492099.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] Leukemia. 2000 Jun;14(6):1143-52 [10865981.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1208-14 [10914544.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):275-81 [11167819.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1485-7 [11516112.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1982-4 [11535539.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):686-94 [11849234.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Lancet Oncol. 2001 Oct;2(10):597-607 [11902549.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):409-17 [11905735.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1971-80 [15470492.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1432-6 [12145681.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):849-51 [14520434.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Br Med J. 1966 Mar 12;1(5488):640-2 [5218168.001]
  • [Cites] Blood. 1980 Sep;56(3):430-41 [6996767.001]
  • [Cites] Leuk Res. 1981;5(4-5):301-9 [7026903.001]
  • [Cites] Blood. 1987 Oct;70(4):1073-8 [3477296.001]
  • [Cites] Blood. 1988 Jul;72(1):299-307 [3291983.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(15):5698-702 [3165197.001]
  • [Cites] Leukemia. 1988 Oct;2(10):628-33 [3172839.001]
  • [Cites] Leukemia. 1989 Feb;3(2):155-8 [2536129.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):5123-7 [2500663.001]
  • [Cites] Blood. 1989 Oct;74(5):1762-7 [2676018.001]
  • [Cites] Blood. 1990 Jul 1;76(1):163-71 [1973061.001]
  • [Cites] Anal Cell Pathol. 1990 Jul;2(4):229-40 [1703434.001]
  • [Cites] Clin Chim Acta. 1991 Apr;198(1-2):93-174 [1863986.001]
  • [Cites] Leukemia. 1991 Aug;5(8):657-67 [1909409.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6061-5 [8327485.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3063-74 [8219197.001]
  • [Cites] Leukemia. 1993 Dec;7(12):2045-53 [7902888.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3930-7 [7579363.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Br J Haematol. 1997 Nov;99(2):314-9 [9375747.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3774-81 [9850021.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Leukemia. 1999 Feb;13(2):196-205 [10025893.001]
  • [Cites] Leukemia. 1999 Mar;13(3):419-27 [10086733.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;246:205-13; discussion 214-5 [10396058.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1221-6 [10450750.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2006 Jul 1;108(1):97-102 [16537802.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Haematologica. 2007 May;92(5):612-8 [17488684.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4022-9 [17720883.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • (PMID = 19825454.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NCI NIH HHS / CA / P30 CA021765; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  • [Other-IDs] NLM/ NIHMS132490; NLM/ PMC2762949
  •  go-up   go-down


20. Landau H, Lamanna N: Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep; 2006 Sep;1(3):171-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults.
  • Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic and prognostic subgroups.
  • The treatment of adults with ALL has evolved largely from the therapy developed for childhood ALL and, despite differences across regimens, can be broadly classified as including induction, consolidation, maintenance, and central nervous system prophylaxis.
  • Although there has been marked improvement in the outcomes for pediatric patients with ALL, the same success has not yet been realized for adult patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / classification. Burkitt Lymphoma / therapy. Central Nervous System / pathology. Child. Clinical Trials as Topic. Cranial Irradiation. Eye / pathology. Hematopoietic Stem Cell Transplantation. Humans. Immunophenotyping. Incidence. Leukemic Infiltration / drug therapy. Leukemic Infiltration / prevention & control. Leukemic Infiltration / radiotherapy. Lymphocyte Subsets / pathology. Male. Neoplasm, Residual. Prognosis. Remission Induction. Testis / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):40-6 [14695849.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] J Clin Oncol. 1983 Aug;1(8):462-70 [6583321.001]
  • [Cites] Lancet. 1996 Jun 29;347(9018):1783-8 [8667921.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:178-81 [1578927.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2480-5 [8823326.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Ann Intern Med. 1995 Sep 15;123(6):428-31 [7639442.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1508-16 [10735899.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • [Cites] Blood. 1980 Feb;55(2):199-204 [6928104.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Blood. 1988 Nov;72(5):1784-9 [3052630.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2032-5 [15483674.001]
  • [Cites] Blood. 1984 Jul;64(1):38-47 [6375764.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):476-82 [9053468.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):323-32 [16091192.001]
  • [Cites] Blood. 1984 Jul;64(1):267-74 [6375760.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):64-6 [3296208.001]
  • [Cites] Jpn J Clin Oncol. 1993 Apr;23(2):85-97 [7685836.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5251-6 [8652840.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1811-22 [11753600.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1603-12 [8068949.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Leukemia. 1991 May;5(5):425-31 [2033963.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4695-700 [12586618.001]
  • [Cites] Leukemia. 2005 May;19(5):734-40 [15789069.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1509-16 [16034462.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):184-8 [12525508.001]
  • (PMID = 20425348.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


21. Svojgr K, Burjanivova T, Vaskova M, Kalina T, Stary J, Trka J, Zuna J: Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia. Immunol Lett; 2009 Feb 21;122(2):185-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia.
  • By influencing proliferation and differentiation, these molecules might play a role in ethiopathogenesis of acute lymphoblastic leukemia (ALL).
  • Moreover, diagnostic samples of childhood ALL cases were analyzed.
  • During normal lymphocyte development, some adaptors show significant dynamics (gradual decrease of NTAL and increase of LAT and LIME during the T-cell maturation, decrease of PAG in B-precursors, high levels of LIME in peripheral B-lymphocytes).
  • Analysis of childhood ALL samples revealed that in B-cell precursor ALL, the TEL/AML1 subgroup have unique adaptor profile compared to other leukemias.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. B-Lymphocytes / metabolism. Lymphopoiesis / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. T-Lymphocytes / metabolism
  • [MeSH-minor] Adaptor Proteins, Vesicular Transport / immunology. Biomarkers, Tumor. Cell Differentiation / immunology. Cell Lineage. Cell Proliferation. Child. Humans. Membrane Proteins / genetics. Membrane Proteins / immunology. Membrane Proteins / metabolism. Signal Transduction / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183565.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adaptor Proteins, Vesicular Transport; 0 / Biomarkers, Tumor; 0 / LAT protein, human; 0 / LAT2 protein, human; 0 / Lck-interacting protein, human; 0 / Membrane Proteins; 0 / PAG1 protein, human
  •  go-up   go-down


22. Dorak MT, McNally RJ, Parker L: Re: "Childhood acute lymphoblastic leukemia and infections in the first year of life: a report from the United Kingdom childhood cancer study". Am J Epidemiol; 2007 Aug 1;166(3):364-5; author reply 365
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: "Childhood acute lymphoblastic leukemia and infections in the first year of life: a report from the United Kingdom childhood cancer study".
  • [MeSH-major] HLA-DP Antigens / genetics. Infection / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


23. Sprehe MR, Barahmani N, Cao Y, Wang T, Forman MR, Bondy M, Okcu MF: Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors. Pediatr Blood Cancer; 2010 Feb;54(2):242-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors.
  • INTRODUCTION: High birth weight (HBW) is an established risk factor for childhood acute lymphoblastic leukemia (ALL).
  • BW was not an independent risk factor for acute myeloid leukemia or brain tumors.

  • MedlinePlus Health Information. consumer health - Birth Weight.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Am J Pathol. 1994 Oct;145(4):802-17 [7943172.001]
  • [Cites] Pediatr Endocrinol Rev. 2009 Feb;6 Suppl 3:332-6 [19404231.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):908-14 [7666480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):441-5 [7549797.001]
  • [Cites] Cancer Causes Control. 1996 Sep;7(5):553-9 [8877054.001]
  • [Cites] Ann Epidemiol. 1997 Apr;7(3):172-9 [9141639.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] J Pediatr. 1997 Nov;131(5):671-7 [9403644.001]
  • [Cites] Am J Perinatol. 1998 Jan;15(1):23-8 [9475683.001]
  • [Cites] J Pediatr. 1999 Feb;134(2):138-40 [9931517.001]
  • [Cites] Matern Child Health J. 2009 Sep;13(5):660-6 [18766434.001]
  • [Cites] Pediatr Int. 2000 Feb;42(1):31-6 [10703231.001]
  • [Cites] J Pediatr Endocrinol Metab. 2000 Mar;13(3):289-96 [10714754.001]
  • [Cites] Matern Child Health J. 1999 Dec;3(4):225-31 [10791363.001]
  • [Cites] Obstet Gynecol. 2000 Nov;96(5 Pt 1):707-13 [11042305.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):935-8 [11158070.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1999 Mar;34(3):135-7 [11263179.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2001 Apr 25;81(8):489-92 [11798925.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):603-13 [11914187.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1078-80 [11953852.001]
  • [Cites] Obstet Gynecol. 2002 Sep;100(3):567-73 [12220780.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):595-602 [12296506.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):922-4; discussion 925 [15128602.001]
  • [Cites] Pediatr Res. 1973 Mar;7(3):132-8 [4511339.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] J Natl Cancer Inst. 1984 May;72(5):1039-41 [6585581.001]
  • [Cites] Pediatr Hematol Oncol. 1994 Nov-Dec;11(6):587-99 [7857782.001]
  • [Cites] Int J Epidemiol. 1999 Aug;28(4):631-9 [10480689.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):125-34 [16021070.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):655-63 [17503007.001]
  • [Cites] Am J Epidemiol. 2007 Jul 15;166(2):151-9 [17443021.001]
  • [Cites] Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12 [17569110.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2658-70 [19173295.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):63-72 [3152913.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3696-701 [2065325.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1351-5 [1873786.001]
  • [Cites] Am J Epidemiol. 1984 May;119(5):788-95 [6720675.001]
  • (PMID = 19813253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057730-13; United States / NCI NIH HHS / CA / R25 CA057730; United States / NCI NIH HHS / CA / R25 CA057730-13; United States / NCI NIH HHS / CA / R25 CA57730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS144377; NLM/ PMC2795053
  •  go-up   go-down


24. Snyder DS, Stein AS, O'Donnell MR, Gaal K, Slovak ML, Forman SJ: Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature. Am J Hematol; 2005 Jan;78(1):74-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature.
  • Survivors of childhood solid tumors including Ewing sarcoma (ES) have an increased risk of secondary malignant neoplasms (SMNs) as a consequence of exposure to chemotherapy and/or radiation (see: Bhatia S, Sklar C.
  • The most common hematologic SMNs are myelodysplasia (MDS) and acute myelogenous leukemia (AML).
  • Acute lymphoblastic leukemia (ALL) is uncommon in this patient population, and Philadelphia chromosome positive (Ph+) ALL in particular, is rare.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Radiation Injuries / complications. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / radiotherapy


25. Crom DB, Tyc VL, Rai SN, Deng X, Hudson MM, Booth A, Rodrigues LN, Zhang L, McCammon E, Kaste SC: Retention of survivors of acute lymphoblastic leukemia in a longitudinal study of bone mineral density. J Child Health Care; 2006 Dec;10(4):337-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retention of survivors of acute lymphoblastic leukemia in a longitudinal study of bone mineral density.
  • Attrition in longitudinal studies of survivors of childhood cancer reduces these studies' statistical power, introduces bias and threatens internal and external validity.
  • This study investigated the variables associated with dropout of survivors of acute lymphoblastic leukemia in a trial investigating the effect of vitamin D and calcium supplementation and nutritional counseling on bone mineral density (BMD).
  • [MeSH-major] Attitude to Health. Longitudinal Studies. Motivation. Patient Dropouts / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Survivors / psychology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101625.001).
  • [ISSN] 1367-4935
  • [Journal-full-title] Journal of child health care : for professionals working with children in the hospital and community
  • [ISO-abbreviation] J Child Health Care
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Sadakane Y, Zaitsu M, Nishi M, Sugita K, Mizutani S, Matsuzaki A, Sueoka E, Hamasaki Y, Ishii E: Expression and production of aberrant PAX5 with deletion of exon 8 in B-lineage acute lymphoblastic leukaemia of children. Br J Haematol; 2007 Jan;136(2):297-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and production of aberrant PAX5 with deletion of exon 8 in B-lineage acute lymphoblastic leukaemia of children.
  • Summary We investigated PAX5 expression in childhood B-lineage acute lymphoblastic leukaemia (ALL).
  • By Western blotting, healthy controls displayed Pax5-FL, while one short Pax5, derived from the deletion of exon 8 (Pax5-DeltaE8) was produced in 90% of ALL samples, as well as in ALL cell lines.
  • PAX5-DeltaE8 lacked more than 50% of the transactivation domain, indicating that aberrant Pax5 production might lead to the arrest of B-cell differentiation, contributing to the pathogenesis of B-lineage ALL.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129225.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / B cell linker protein; 0 / B-Cell-Specific Activator Protein; 0 / RNA, Messenger
  •  go-up   go-down


27. Ribera JM, Oriol A: Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am; 2009 Oct;23(5):1033-42, vi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in adolescents and young adults.
  • Today, long-term survival is achieved in more than 80% of children 1 to 10 years old with acute lymphoblastic leukemia (ALL).
  • Within childhood ALL populations, older children have shown inferior outcomes, whereas younger adults have shown superior outcomes among adult ALL patients.
  • The type of treatment (pediatric-based versus adult-based) for AYA has recently been a matter of debate.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825451.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


28. Samochatova EV, Chupova NV, Rudneva A, Makarova O, Nasedkina TV, Fedorova OE, Glotov AS, Kozhekbaeva Zh, Maiorova OA, Roumyantsev AG, Krynetski EY, Krynetskaia NF, Evans WE, Ribeiro RC: TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer; 2009 Feb;52(2):203-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed allele frequencies in the whole cohort, the childhood cancer group, and the non-cancer group.
  • We also characterized disease features and outcome according to the presence of TPMT SNPs in children with acute lymphoblastic leukemia (ALL).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Pharm Res. 1999 Mar;16(3):342-9 [10213363.001]
  • [Cites] Pharmacogenetics. 1999 Feb;9(1):37-42 [10208641.001]
  • [Cites] Science. 1999 Oct 15;286(5439):487-91 [10521338.001]
  • [Cites] J Biol Chem. 1963 Mar;238:1078-84 [13981612.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Eur J Cancer. 1999 Sep;35(9):1349-55 [10658526.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Eur J Hum Genet. 2006 Sep;14(9):991-8 [16724002.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Pharmacology. 2000 Sep;61(3):136-46 [10971199.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Drug Metab Dispos. 2001 Apr;29(4 Pt 2):601-5 [11259360.001]
  • [Cites] Pharmacogenetics. 2001 Apr;11(3):275-8 [11337944.001]
  • [Cites] Clin Pharmacol Ther. 2001 Aug;70(2):183-8 [11503013.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):191-5 [11927834.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):353-9 [12142782.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5620-9 [14654544.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Pharmacogenetics. 2004 Jul;14(7):407-17 [15226673.001]
  • [Cites] Ther Drug Monit. 2004 Oct;26(5):541-5 [15385838.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1816-23 [2585022.001]
  • [Cites] Clin Pharmacol Ther. 1994 Jan;55(1):15-20 [8299312.001]
  • [Cites] Pediatr Hematol Oncol. 1994 May-Jun;11(3):251-8 [8060809.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):949-53 [7862671.001]
  • [Cites] Mol Pharmacol. 1995 Jun;47(6):1141-7 [7603453.001]
  • [Cites] DNA Cell Biol. 1996 Apr;15(4):273-80 [8639263.001]
  • [Cites] Am J Hum Genet. 1996 Apr;58(4):694-702 [8644731.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Clin Pharmacol Ther. 1998 Jul;64(1):46-51 [9695718.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):367-70 [9931345.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):371-6 [9931346.001]
  • [Cites] Blood. 1999 May 1;93(9):2817-23 [10216075.001]
  • (PMID = 19034904.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  • [Other-IDs] NLM/ NIHMS123733; NLM/ PMC2794198
  •  go-up   go-down


29. Fujita N, Mori T, Mitsui T, Inada H, Horibe K, Tsurusawa M, Lymphoma Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group: The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer; 2008 Aug;51(2):188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan.
  • BACKGROUND: There have been excellent treatment results for children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell leukemia (B-ALL) in the last few decades.
  • Among 18 patients who had a chemotherapy-sensitive disease, 4 of 5 patients who underwent hematopoietic stem cell transplantation (HSCT) during remission survived without progression, while 3 of 12 patients who did not receive HSCT were alive without disease progression.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, B-Cell / therapy. Lymphoma, B-Cell / therapy


30. Hori H: [Treatment strategy for childhood and adolescent acute lymphoblastic leukemia in first remission]. Rinsho Ketsueki; 2010 Jul;51(7):454-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategy for childhood and adolescent acute lymphoblastic leukemia in first remission].
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chromosome Aberrations. Hematopoietic Stem Cell Transplantation. Humans. Infant. Remission Induction. Survival Rate


31. Timson G, Banavali S, Gutierrez MI, Magrath I, Bhatia KG, Goyns MH: High level expression of N-acetylgluosamine-6-O-sulfotransferase is characteristic of a subgroup of paediatric precursor-B acute lymphoblastic leukaemia. Cancer Lett; 2006 Oct 28;242(2):239-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level expression of N-acetylgluosamine-6-O-sulfotransferase is characteristic of a subgroup of paediatric precursor-B acute lymphoblastic leukaemia.
  • Recently microarray analysis has identified a novel subgroup of childhood precursor-B acute lymphoblastic leukaemia (ALL) from a unique gene expression profile of over 30 genes.
  • The levels of expression of N-acetylglucosamine-6-O-sulfotransferase (GN6ST), protein tyrosine phosphatase receptor M (PTPRmu), G protein-coupled receptor 49 (HG38) and KIAA1099 protein were determined in childhood precursor-B ALL samples from a cohort of 116 Indian patients.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Sulfotransferases / biosynthesis
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Child. Child, Preschool. DNA Primers. Humans. Infant. Infant, Newborn. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386360.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.- / carbohydrate sulfotransferases
  •  go-up   go-down


32. Pakakasama S, Veerakul G, Sosothikul D, Chainansamit SO, Laosombat V, Thanarattanakorn P, Lumkul R, Wiangnon S, Wangruangsathit S, Narkbunnam N, Kanjanapongkul S: Late effects in survivors of childhood acute lymphoblastic leukemia: a study from Thai Pediatric Oncology Group. Int J Hematol; 2010 Jun;91(5):850-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects in survivors of childhood acute lymphoblastic leukemia: a study from Thai Pediatric Oncology Group.
  • Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk of long-term late effects.
  • We performed a cross-sectional study for evaluation of the late effects in ALL survivors who came for follow-up at 10 pediatric oncology centers in Thailand.
  • Our data have demonstrated a significant prevalence of late effects after childhood ALL therapy.
  • A long-term follow-up program for survivors of childhood cancer is therefore needed in our country.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):211-31, v-vi [18395146.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):320-8 [11979456.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Clin Pediatr (Phila). 2009 Jul;48(6):601-8 [19264722.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):118-22 [18338394.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] Asian Pac J Cancer Prev. 2003 Aug-Dec;4(4):337-43 [14728593.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):881-91 [16035086.001]
  • [Cites] J Pediatr Endocrinol Metab. 2004 May;17(5):719-26 [15237705.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5515-23 [18334672.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1183-9 [17401007.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):251-73, xiii [18242324.001]
  • [Cites] Obes Rev. 2009 Nov;10(6):589-92 [19656310.001]
  • [Cites] CA Cancer J Clin. 2004 Jul-Aug;54(4):208-36 [15253918.001]
  • [Cites] Blood Cells Mol Dis. 2003 Jul-Aug;31(1):84-92 [12850490.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):266-8 [11920793.001]
  • [Cites] J Pediatr. 2008 Apr;152(4):458-66 [18346496.001]
  • (PMID = 20490729.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


33. Ravikumara M, Hill FG, Wilson DC, Gillett PM, Thomas A, Brown R, Darbyshire PJ, McKiernan PJ: 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience. J Pediatr Gastroenterol Nutr; 2006 May;42(5):535-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience.
  • BACKGROUND: 6-Thioguanine treatment in childhood acute lymphoblastic leukaemia (ALL) has been shown to cause hepatic veno-occlusive disease, but this usually resolved with drug withdrawal.
  • Two children presented with acute variceal bleeding.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Drug-Induced Liver Injury, Chronic / etiology. Esophageal and Gastric Varices / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thioguanine / adverse effects

  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707977.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


34. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer; 2008 Jan;44(2):257-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
  • PURPOSE: To investigate the cumulative incidence of and the risk factors for developing second malignant neoplasms (SMN) in children and adolescents following treatment for relapse of acute lymphocytic leukaemia (ALL).
  • METHODS: Patients (1376) up to 18 years of age with first relapse of non-B-cell ALL were treated and achieved a 2nd complete remission (CR).
  • RESULTS: Out of the 1376 patients 21 were diagnosed with SMN including non-lymphoblastic leukaemia/myelodysplastic syndrome (n=6), osteo-/Ewing's-/fibroblastic sarcoma (n=4), B-cell ALL/lymphoma (n=2), thyroid carcinoma (n=2), basal cell carcinoma, adeno carcinoma, squamous cell carcinoma, meningioma, malignant histiocytosis, glioblastoma and anaplastic astrocytoma (n=1 each).
  • SMN was found to be significantly associated with stem cell transplantation (SCT), and high cumulative doses of cranial irradiation, etoposide and cyclophosphamide.
  • CONCLUSIONS: Despite repeated exposure to intense frontline and relapse treatment (including multiagent chemotherapy, cranial irradiation and stem cell transplantation in some patients) the cumulative incidence of SMN was unexpectedly low, though significantly higher than in the general age-matched population.
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981026.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Mertens R; Imbach P; Pongratz E; Rupprecht T; Henze G; Wickmann L; Otte J; Bode U; Eberl W; Pekrun A; Kirschstein M; Hofmann K; Frank R; Möbius D; Andler W; Niekrens C; Breu H; Suttorp M; Göbel U; Weinmann G; Sauerbrey A; Beck JF; Janka-Schaub G; Welte K; Kulozik A; Tautz C; Graf N; Fink FM; Zintl F; Hermann J; Rupprath G; Dupuis W; Rodehüser M; Schrappe M; Berthold F; Sternschulte W; Körholz D; Schmitt K; Selle B; Gutjahr P; Dürken M; Christiansen H; Rose M; Borkhardt A; Burdach S; Jürgens H; Scheurlen W; Eggers G; Geib R; Dickerhoff R; Bielack S; Rauh W; Niethammer D; Debatin KM; Gadner H; Dohrn B; Schlegel PG; Niggli F
  •  go-up   go-down


35. Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S: Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer; 2010 May 1;126(9):2216-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis.
  • Escape of apoptosis may contribute to treatment failure in childhood acute lymphoblastic leukemia (ALL) calling for new approaches to overcome apoptosis resistance.
  • Thus, small molecule XIAP inhibitors present a promising novel approach to enhance CD95-induced apoptosis in childhood acute leukemia.
  • [MeSH-major] Antigens, CD95 / physiology. Apoptosis / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / antagonists & inhibitors
  • [MeSH-minor] Caspases / metabolism. Cell Line, Tumor. Child. Fas Ligand Protein / physiology. Humans. Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19676052.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; EC 3.4.22.- / Caspases
  •  go-up   go-down


36. Campana D: Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep; 2010 Jul;5(3):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress of minimal residual disease studies in childhood acute leukemia.
  • Submorphologic (ie, minimal) residual disease (MRD) can be monitored in virtually all children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) using methods such as flow cytometric detection of leukemic immunophenotypes or polymerase chain reaction amplification of fusion transcripts, gene mutations, and clonal rearrangements of antigen-receptor genes.
  • This article discusses the methods used for detecting MRD in childhood AML and ALL, the data obtained in studies correlating MRD with treatment outcome, the results of the initial trials using MRD, and the practical aspects related to the design of MRD-based clinical studies.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467922.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115422; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA115422; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  • [Other-IDs] NLM/ NIHMS791266; NLM/ PMC4898261
  •  go-up   go-down


37. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Bührer C, Henze G, Seeger K, Wellmann S: The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res; 2006 Sep 15;12(18):5526-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
  • PURPOSE: Thalidomide and its analogues have shown promise in the treatment of multiple myeloma but their therapeutic potential has not been evaluated in models of acute lymphoblastic leukemia (ALL).
  • EXPERIMENTAL DESIGN: We assessed the effects of the thalidomide analogue, CC-4047, on the growth and apoptosis signaling of human B cell precursor (BCP) ALL cell lines and freshly obtained childhood BCP-ALL cells grown with or without stromal cells.
  • RESULTS: CC-4047 reduced the proliferation of human BCP-ALL cell lines in vitro.
  • In contrast with the antileukemic effect of cytarabin, this was more pronounced when cell lines or freshly obtained childhood BCP-ALL cells were cocultured with stromal cells.
  • The inhibition of tumor growth, caspase-3 cleavage, and reduced microvessel density was observed in nonobese diabetic/severe combined immunodeficiency mice inoculated s.c. with childhood BCP-ALL cells upon CC-4047 treatment.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thalidomide / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000689.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; D2UX06XLB5 / pomalidomide; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


38. Webb D, Roberts I, Vyas P: Haematology of Down syndrome. Arch Dis Child Fetal Neonatal Ed; 2007 Nov;92(6):F503-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, benign abnormalities of the blood count and blood film, which may manifest at any age, population-based and cancer-based registries and clinical trials suggest there is a approximately 12-fold increased risk of acute lymphoblastic leukaemia in the age group of 5-30 years that rises to approximately 40-fold in children younger than 5 years, and that there is a approximately 150-fold increased risk of acute myeloid leukaemia in children younger than 5 years.
  • It also briefly considers the recent exciting scientific advances that have potential to transform management of leukaemia in children with Down syndrome and also have implications for management of childhood leukaemia more generally.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):548-51 [15686466.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1223-31 [15860665.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(19):8592-606 [16166640.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):3-7 [16173956.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4043-9 [16109782.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):744-7 [16356423.001]
  • [Cites] Blood. 2006 Jan 1;107(1):87-97 [16144799.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):576-83 [16445830.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4606-13 [16469874.001]
  • [Cites] Early Hum Dev. 2006 Dec;82(12):767-73 [17064858.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):797-804 [15755283.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):523-7 [10598665.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Arch Dis Child. 2001 Oct;85(4):321-5 [11567943.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Leukemia. 2003 Feb;17(2):277-82 [12592323.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):930-8 [12648061.001]
  • [Cites] Lancet. 2003 May 10;361(9369):1617-20 [12747884.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4301-4 [12586620.001]
  • [Cites] Ultrasound Obstet Gynecol. 2003 May;21(5):486-9 [12768562.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2960-8 [12816863.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2480-9 [14656875.001]
  • [Cites] Am J Med Genet. 1983 Oct;16(2):173-7 [6228141.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):1057-63 [1825025.001]
  • [Cites] Pediatr Hematol Oncol. 1992 Apr-Jun;9(2):139-49 [1388043.001]
  • [Cites] Clin Genet. 1996 Jan;49(1):15-9 [8721566.001]
  • [Cites] Pediatr Hematol Oncol. 1996 May-Jun;13(3):271-5 [8735344.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1677-86 [8892666.001]
  • [Cites] Blood. 1998 Jan 15;91(2):608-15 [9427716.001]
  • [Cites] Leukemia. 1998 May;12(5):645-51 [9593260.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 1998 Nov;79(3):F215-7 [10194996.001]
  • [Cites] Pediatr Res. 1999 Jul;46(1):28-32 [10400130.001]
  • [Cites] Arch Dis Child. 1999 Jul;81(1):32-7 [10373130.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):33-9 [15390307.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1355-60 [15920490.001]
  • (PMID = 17804520.001).
  • [ISSN] 1468-2052
  • [Journal-full-title] Archives of disease in childhood. Fetal and neonatal edition
  • [ISO-abbreviation] Arch. Dis. Child. Fetal Neonatal Ed.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 37
  • [Other-IDs] NLM/ PMC2675407
  •  go-up   go-down


39. Alavi S, Ashraf H, Rashidi A, Hosseini N, Abouzari M, Naderifar M: Distribution of ABO blood groups in childhood acute leukemia. Pediatr Hematol Oncol; 2006 Dec;23(8):611-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of ABO blood groups in childhood acute leukemia.
  • The distribution of ABO blood groups was determined in a multicenter study of 682 pediatric patients with acute lymphoblastic leukemia (ALL) and 224 patients with acute myeloid leukemia (AML) up to 12 years old.
  • [MeSH-major] ABO Blood-Group System / analysis. Leukemia, Myeloid / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Female. Gene Frequency. Humans. Infant. Iran / epidemiology. Male. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065136.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


40. Xavier AC, Ge Y, Taub JW: Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn; 2009 Sep;11(5):371-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DS children have a approximately 10- to 20-fold higher risk for developing acute lymphoblastic leukemia and acute myeloid leukemia (AML), as compared with non-DS children, although they do not have a uniformly increased risk of developing solid tumors.
  • DS children with acute lymphoblastic leukemia frequently experience higher levels of treatment-related toxicity and inferior event-free survival rates, as compared with non-DS children.
  • DS children also develop AML with unique features and have a 500-fold increased risk of developing the AML subtype, acute megakaryocytic leukemia (AMkL; M7).
  • In addition, somatic mutations of the GATA1 gene have been detected in nearly all DS TMD and AMkL cases and not in leukemia cases in non-DS children.
  • Examining leukemogenesis in DS children may identify factors linked to the general development of childhood leukemia and lead to potential new therapeutic strategies to fight this disease.
  • [MeSH-minor] Animals. Disease-Free Survival. GATA1 Transcription Factor / genetics. Humans. Leukemia, Megakaryoblastic, Acute / epidemiology. Leukemia, Megakaryoblastic, Acute / etiology. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2008 Aug;93(8):1262-3 [18519512.001]
  • [Cites] Br J Haematol. 2008 Aug;142(4):610-5 [18510680.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2572-7 [18829445.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1813-7 [18754026.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jan;52(1):14-9 [18802938.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4507-11 [18689547.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4503-6 [18812473.001]
  • [Cites] Eur J Haematol. 2009 Jan;82(1):46-53 [19067745.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1575-83 [17971484.001]
  • [Cites] Blood. 2002 Jan 1;99(1):245-51 [11756178.001]
  • [Cites] Leuk Res. 1994 Mar;18(3):163-71 [8139285.001]
  • [Cites] Med Pediatr Oncol. 1995 May;24(5):305-9 [7700182.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3395-403 [8605357.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Med Hypotheses. 1996 Apr;46(4):393-9 [8733171.001]
  • [Cites] Eur J Hum Genet. 2001 Nov;9(11):811-4 [11781696.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):428-36 [11794699.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):147-52 [11809723.001]
  • [Cites] Bull Acad Natl Med. 2001;185(7):1239-52; discussion 1252-4 [11975321.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Leukemia. 2003 Feb;17(2):277-82 [12592323.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):930-8 [12648061.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):197-9 [12714896.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4301-4 [12586620.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3415-22 [12885836.001]
  • [Cites] Blood. 2004 Jan 1;103(1):366 [14684662.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):728-35 [14744791.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2480-9 [14656875.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):19-25 [15061193.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1588-9 [15317736.001]
  • [Cites] Lancet. 1986 Oct 18;2(8512):914 [2876340.001]
  • [Cites] Eur J Pediatr. 1987 Jul;146(4):416-22 [2958283.001]
  • [Cites] Am J Med Genet Suppl. 1990;7:204-12 [2149949.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):993-9 [2069856.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2210-4 [1384797.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1266-9 [9182298.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Blood. 1998 Jan 15;91(2):608-15 [9427716.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):448-52 [9458088.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1393-400 [10438727.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1866-72 [15520821.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):21-8 [15368546.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):33-9 [15390307.001]
  • [Cites] Semin Cell Dev Biol. 2005 Feb;16(1):137-47 [15659348.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):226-31 [15687366.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):797-804 [15755283.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):405-10 [15952191.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1355-60 [15920490.001]
  • [Cites] Leuk Res. 2005 Nov;29(11):1353-6 [15916804.001]
  • [Cites] Ophthalmic Genet. 2005 Sep;26(3):151-2 [16272063.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4043-9 [16109782.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):748-52 [16356424.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jan 6;54(51):1301-5 [16397457.001]
  • [Cites] Leukemia. 2006 Feb;20(2):381-3 [16341038.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):576-83 [16445830.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1570-81 [16249385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Br J Haematol. 2006 Jun;133(6):646-8 [16704441.001]
  • [Cites] J Pediatr. 2006 May;148(5):687-9 [16737888.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4606-13 [16469874.001]
  • [Cites] Pediatrics. 2006 Nov;118(5):e1499-508 [17030598.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):624-8 [17610268.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2128-31 [17576817.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):2067-74 [17849462.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5442-7 [18048827.001]
  • [Cites] Nature. 2008 Jan 3;451(7174):73-5 [18172498.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):414-20 [18202418.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Leukemia. 2000 May;14(5):943-4 [10803530.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):175-8 [11305722.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3727-32 [11389009.001]
  • [Cites] Blood. 2001 Jul 1;98(1):85-92 [11418466.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;67:131-62 [11525381.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2681-8 [11675338.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2991-8 [18182574.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1428-30 [18059480.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):515-21 [18521927.001]
  • (PMID = 19710397.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120772
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Number-of-references] 87
  • [Other-IDs] NLM/ PMC2729834
  •  go-up   go-down


41. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J: Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer; 2008 Sep;51(3):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of childhood acute lymphoblastic leukemia treated in China.
  • Of these, 248 patients received modified National Protocol of Childhood ALL in China 1997 (NPCAC97) for at least 2 weeks of treatment and were eligible for protocol evaluation.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Treatment Failure. Treatment Refusal

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18506765.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Ozdemir MA, Karakukcu M, Patiroglu T, Torun YA, Kose M: Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia. Acta Haematol; 2009;121(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.
  • INTRODUCTION: The standard management of childhood acute lymphoblastic leukemia with hyperleukocytosis is unclear and its treatment has focused on prompt leukocytoreduction.
  • METHODS: In the present prospective trial, 15 children with acute lymphoblastic leukemia and hyperleukocytosis (range 101-838 x 10(9)/l) were treated with intravenous low-dose prednisone continuous infusion (6 mg/m(2)/24 h).
  • RESULTS: The mean reduction in white blood cell count achieved by this treatment was 34.4% on first day, 56.9% on second day and 76.6% on third day.
  • CONCLUSIONS: Intravenous low-dose prednisone continuous infusion treatment can prevent the progression to tumor lysis syndrome and it may be used for the patients presenting with white blood cell counts between 100 and 400 x 10(9)/l in centers where leukoapheresis is not readily available.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Leukocytosis / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / administration & dosage. Tumor Lysis Syndrome / prevention & control

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19339772.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; VB0R961HZT / Prednisone
  •  go-up   go-down


43. Markaki EA, Stiakaki E, Zafiropoulos A, Arvanitis DA, Katzilakis N, Dimitriou H, Spandidos DA, Kalmanti M: Mutational analysis of the cell cycle inhibitor Kip1/p27 in childhood leukemia. Pediatr Blood Cancer; 2006 Jul;47(1):14-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analysis of the cell cycle inhibitor Kip1/p27 in childhood leukemia.
  • BACKGROUND: Cyclin-dependent kinases (CDKs) and cyclins, their regulatory subunits, govern cell-cycle progression in eukaryotic cells.
  • Kip1/p27 is the main cyclin-dependent kinase inhibitor, which arrests cell division inhibiting G1-S transition.
  • METHODS: Bone marrow blasts from 49 children with leukemia, 37 acute lymphoblastic leukemia (ALL), and 12 acute myeloid leukemia (AML) were studied.
  • Although the patient groups are small, a highly significant relation of the mutation status with the type of leukemia (P = 0.0037) and the risk group according to treatment protocols (P = 0.00021) was estimated.
  • CONCLUSIONS: Based upon these results, the Kip1/p27 mutations should be considered for further prospective testing as an additional parameter for risk stratification and treatment of childhood leukemia.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Leukemia, Myeloid / genetics. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Bone Marrow / pathology. Cell Cycle / drug effects. Child. Child, Preschool. DNA Mutational Analysis. Female. Humans. Infant. Male. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16526056.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


44. Leone G, Fianchi L, Pagano L, Voso MT: Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact; 2010 Mar 19;184(1-2):39-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapy-related myeloid neoplasms (t-MN) include acute myeloid leukemias and myelodysplastic syndromes arising in patients who have been treated with chemotherapy, radiation therapy, immunosuppressive agents or after documented exposure to environmental carcinogen. t-MN are defined according to the primary treatment and the corresponding genetic and molecular lesions.
  • Patients with lymphoma are at highest risk if total body irradiation followed by autologous stem cell transplantation is used as rescue or consolidation.
  • The addition of granulocyte-colony stimulating factor (G-CSF) and radiotherapy plays a significant role in t-MN following treatment of childhood acute lymphoblastic leukemia.
  • In solid tumors, treatment for breast cancer and germ-cell tumors has been associated with a 1-5% lifetime risk of t-MN.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Myelodysplastic Syndromes / epidemiology. Myelodysplastic Syndromes / etiology. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20026017.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Topoisomerase II Inhibitors; J64922108F / Benzene
  •  go-up   go-down


45. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group: Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer; 2006 Oct 1;107(7):1551-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.
  • BACKGROUND: Several studies have reported a more favorable outcome for teenagers and young adults with acute lymphoblastic leukemia (ALL) when they were treated in pediatric oncology departments compared with adult hematology departments.
  • METHODS: In Sweden during the 1990s, adolescents with ALL were treated in a pediatric oncology unit or in an adult hematologic unit, depending on the initial referral.
  • In the current national, comparative, retrospective study, patients with ALL aged 10 years to 40 years who were treated either according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocol (1992-2000) (NOPHO-92 protocol) or according to the Swedish Adult ALL Group protocol (1994-2000) (Adult protocol) were included.
  • RESULTS: In total, 243 patients with B-precursor and T-cell ALL were treated according to the protocols.
  • CONCLUSIONS: The NOPHO-92 protocol resulted in a better outcome than the Adult protocol; therefore, adolescents may benefit from the pediatric protocol treatment strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955505.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. McNally RJ, Alexander FE, Vincent TJ, Murphy MF: Spatial clustering of childhood cancer in Great Britain during the period 1969-1993. Int J Cancer; 2009 Feb 15;124(4):932-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial clustering of childhood cancer in Great Britain during the period 1969-1993.
  • The aetiology of childhood cancer is poorly understood.
  • To determine whether localized environmental factors may play a part in childhood cancer aetiology, we analyzed for spatial clustering using a large set of national population-based data from Great Britain diagnosed 1969-1993.
  • Analyses showed statistically significant evidence of clustering for acute lymphoblastic leukaemia (ALL) over the whole age range (estimate of EPV = 0.05, p = 0.002) and for ages 1-4 years (estimate of EPV = 0.03, p = 0.015).
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cluster Analysis. Environmental Exposure. Female. Great Britain. Humans. Infant. Infant, Newborn. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Residence Characteristics. Sarcoma / diagnosis. Sarcoma / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035447.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Cao L, Guo B, Kang R, Yang M, Zhang Z, Wu X: Identification of a 2-cM minimal deletion at 6q16.3-21 in childhood acute lymphoblastic leukemia in China. Pediatr Blood Cancer; 2005 Oct 15;45(5):732-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a 2-cM minimal deletion at 6q16.3-21 in childhood acute lymphoblastic leukemia in China.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 6 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


48. Dengel DR, Ness KK, Glasser SP, Williamson EB, Baker KS, Gurney JG: Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Jan;30(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Adult survivors of childhood acute lymphoblastic leukemia (ALL) have an earlier than expected mortality from cardiovascular disease.
  • This study examined endothelial function in 75 young (age 30.2+/-7.1 y) adult survivors of childhood ALL who received chemotherapy without cranial radiation (n=25) or chemotherapy combined with cranial radiation (n=50) compared with a healthy control group of similar sex, age, and weight (n=59).
  • CONCLUSIONS: These data suggest that young adults treated for ALL during childhood are at risk for impaired FMD regardless of whether or not they received cranial irradiation.
  • The extent to which this mechanism relates to early development of cardiovascular disease in long-term childhood ALL survivors remains to be determined.
  • [MeSH-major] Brachial Artery / physiopathology. Endothelium, Vascular / physiopathology. Nitroglycerin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Vasodilation / drug effects. Vasodilator Agents / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITROGLYCERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176175.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00400; United States / NCI NIH HHS / CA / R21-CA106778; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasodilator Agents; G59M7S0WS3 / Nitroglycerin
  •  go-up   go-down


49. Tavernier E, Le QH, de Botton S, Dhédin N, Bulabois CE, Reman O, Vey N, Lhéritier V, Dombret H, Thomas X: Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. Cancer; 2007 Dec 15;110(12):2747-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials.
  • BACKGROUND: Second malignant neoplasms are a serious complication after successful treatment of childhood acute lymphoblastic leukemia (ALL).
  • RESULTS: By February 2005 secondary or concomitant neoplasms were documented in 23 patients, including 9 acute myeloid leukemias (AML) or myelodysplasias (MDS), 4 non-Hodgkin lymphomas (NHL), 5 skin tumors, and 5 other solid tumors (1 lung cancer, 1 tongue carcinoma, 1 thymoma, 1 condrosarcoma, 1 histiocytosis).
  • The risk of secondary or concomitant neoplasm appeared higher than that of childhood ALL previously reported in the literature.
  • Considering the low survival rate of this large unselected adult ALL cohort (32% at 10 years) as compared with that observed in childhood ALL, the risk of second malignancy remains underestimated.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


50. Tedeschi R, Bloigu A, Ogmundsdottir HM, Marus A, Dillner J, dePaoli P, Gudnadottir M, Koskela P, Pukkala E, Lehtinen T, Lehtinen M: Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring. Am J Epidemiol; 2007 Jan 15;165(2):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring.
  • After identifying an association between maternal Epstein-Barr virus (EBV) reactivation and acute lymphoblastic leukemia (ALL), the authors analyzed a nested case-control study within Finnish and Icelandic maternity cohorts with 7 million years of follow-up to confirm EBV's role in ALL.
  • Offspring of 550,000 mothers were followed up to age 15 years during 1975-1997 by national cancer registries to identify leukemia cases.
  • EBV reactivation may be associated with a proportion of childhood leukemia.
  • [MeSH-major] Antigens, Viral / immunology. Capsid Proteins / immunology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / immunology. Maternal Exposure. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005627.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / Epstein-Barr viral capsid antigen; 0 / Immunoglobulin G
  •  go-up   go-down


51. Cooley LD, Chenevert S, Shuster JJ, Johnston DA, Mahoney DH, Carroll AJ, Devidas M, Linda SB, Lauer SJ, Camitta BM: Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Cancer Genet Cytogenet; 2007 Jun;175(2):117-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
  • Chromosome anomalies have been shown to have prognostic significance in children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 21 / genetics. Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17556067.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA030969; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Ansari M, Krajinovic M: Pharmacogenomics of acute leukemia. Pharmacogenomics; 2007 Jul;8(7):817-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenomics of acute leukemia.
  • Leukemia exists in two different forms, myeloid and lymphoid.
  • Acute lymphoblastic leukemia more frequently occurs in children, whereas the risk of acute myeloid leukemia is more common in adults.
  • Prognosis is particularly poor in adult acute myeloid leukemia.
  • Treatment failure in childhood acute lymphoblastic leukemia due to drug resistance remains the leading cause of cancer-related death in children.
  • Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Pharmacogenetics
  • [MeSH-minor] Child. Humans. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240908.001).
  • [ISSN] 1744-8042
  • [Journal-full-title] Pharmacogenomics
  • [ISO-abbreviation] Pharmacogenomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 130
  •  go-up   go-down


53. Sanders JE, Guthrie KA, Hoffmeister PA, Woolfrey AE, Carpenter PA, Appelbaum FR: Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood; 2005 Feb 1;105(3):1348-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final adult height of patients who received hematopoietic cell transplantation in childhood.
  • Growth impairment and growth hormone (GH) deficiency are complications after total body irradiation (TBI) and hematopoietic cell transplantation (HCT).
  • Girls (P = .0001) and children diagnosed with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or myelodysplastic syndromes (MDS) (compared with acute lymphoblastic leukemia [ALL] or non-Hodgkin lymphoma [NHL]; P = .02) also showed more rapid growth than their counterparts.
  • [MeSH-major] Body Height. Growth / physiology. Hematologic Neoplasms / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2005 Oct 1;106(7):2592-3; author reply 2593 [16172255.001]
  • (PMID = 15454481.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


54. Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ, Petryk A, Steinberger J, Anderson FS, Baker KS: Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer; 2007 Dec;49(7):958-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age.
  • BACKGROUND: Hematopoeitic cell transplantation (HCT) in childhood has been associated with late complications including endocrine, neurocognitive, and cardiopulmonary abnormalities.
  • PROCEDURE: Eligible subjects underwent HCT for acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) at less than 3 years of age.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning


55. Taylor GM, Richards S, Wade R, Hussain A, Simpson J, Hill F, Mitchell C, Eden T, UKCCS and CCLG Investigators: Relationship between HLA-DP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease? Br J Haematol; 2009 Apr;145(1):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between HLA-DP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease?
  • We recently reported that two of six HLA-DP supertypes (DP1-4, 6, 8) were associated with susceptibility (DP2) and resistance (DP1) to childhood acute lymphoblastic leukaemia (ALL).
  • To determine whether DP supertypes are associated with childhood ALL prognosis, we compared treatment outcomes in a cohort (n = 798) of DPB1-typed ALL cases in the UK Medical Research Council UKALL XI trial.
  • This may involve abrogation of DP1/3-restricted T-cell control of residual disease due to selective effects of chemotherapy.
  • Further studies of HLA supertypes in relation to outcome in recent childhood ALL trials may resolve this question.
  • [MeSH-major] Biomarkers, Tumor / genetics. HLA-DP Antigens / genetics. Neoplasm, Residual / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2011 Apr;153(1):131-3 [21275963.001]
  • (PMID = 19183185.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA-DP Antigens; 0 / HLA-DP beta-Chains; 0 / HLA-DPw1 antigen; 0 / HLA-DPw2 antigen; 0 / HLA-DPw3 antigen; 0 / HLA-DPw4 antigen; 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA: Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer; 2008 Apr;50(4):854-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
  • BACKGROUND: The objective of this study was to determine risk factors associated with abnormal timing of menarche among survivors of childhood acute lymphoblastic leukemia (ALL).
  • PROCEDURE: Self-reported age of menarche was determined among 949 female ALL survivors participating in the Childhood Cancer Survivor Study (CCSS), a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986, and compared with 1,128 siblings.
  • CONCLUSIONS: Few female childhood ALL survivors experienced menarche outside of the normal range.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Menarche / drug effects. Menarche / radiation effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Radiotherapy / adverse effects


57. Stanulla M, Schäffeler E, Arens S, Rathmann A, Schrauder A, Welte K, Eichelbaum M, Zanger UM, Schrappe M, Schwab M: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol; 2005 Jan;81(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia.
  • The probability of event-free survival of childhood acute lymphoblastic leukemia (ALL) approaches 80% or more with the use of modern multiagent chemotherapeutic regimens.
  • In a matched case-control study, we investigated the associations between CNS relapse in childhood ALL and the presence of phenotypically relevant single nucleotide polymorphisms within the GSTP1 (codon 105 and 114) and MDR1 genes (ABCB1; coding for Pgp; exon 26, C3435T).
  • These results suggested a modulating role for host genetic variation in the development of CNS relapse in childhood ALL treated according to Berlin-Frankfurt-Münster protocols.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Glutathione Transferase / genetics. Isoenzymes / genetics. P-Glycoprotein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] J Clin Invest. 1996 Jun 1;97(11):2517-24 [8647944.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Pharmacol Ther. 1990;48(3):357-69 [2084706.001]
  • [Cites] Pharmacogenetics. 1998 Feb;8(1):27-31 [9511178.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):397-402 [9299520.001]
  • [Cites] Blood. 1994 Jul 15;84(2):355-66 [8025264.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:161-83 [8725386.001]
  • [Cites] Gastroenterology. 2000 Feb;118(2):279-88 [10648456.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1847-54 [12089380.001]
  • [Cites] N Engl J Med. 2003 Apr 10;348(15):1442-8 [12686700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 [10716719.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):641-4 [9111193.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Aug;16(4):293-303 [2234311.001]
  • [Cites] Eur J Haematol. 2004 May;72(5):314-21 [15059065.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Jan 21;55(1):83-105 [12535575.001]
  • [Cites] Joint Bone Spine. 2000 Jan;67(1):30-9 [10773966.001]
  • [Cites] Ann Hum Genet. 1989 Jul;53(Pt 3):205-13 [2596826.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Pharmacogenetics. 2001 Jun;11(4):293-8 [11434506.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Pharmacogenetics. 2000 Nov;10(8):715-26 [11186134.001]
  • [Cites] Eur J Biochem. 1994 Sep 15;224(3):893-9 [7925413.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:285-307 [12359865.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 15717687.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / P-Glycoprotein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


58. Mkrtchyan H, Garcia Ney DR, de Ventura ES, Liehr T, Felix GR, Marques-Salles Tde J, Abdelhay E, Macedo Silva ML: Molecular cytogenetic studies characterize a near-triploid complex karyotype in a child with acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2010 Feb;197(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic studies characterize a near-triploid complex karyotype in a child with acute lymphoblastic leukemia.
  • High hyperdiploidy with modal chromosome numbers between 50 and 65 is common in childhood acute lymphoblastic leukemia (ALL), occurring in 25-30% of the cases.
  • By contrast, near triploidy and tetraploidy are found in <1% of childhood ALL.
  • [MeSH-major] Chromosome Aberrations. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20113840.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Kostić G, Jovancić D, Saranac L, Bjelaković B: [Neurotoxicity during induction treatment of childhood acute lymphoblastic leukaemia--two case reports]. Srp Arh Celok Lek; 2009 May-Jun;137(5-6):266-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurotoxicity during induction treatment of childhood acute lymphoblastic leukaemia--two case reports].
  • INTRODUCTION: During chemotherapy of acute lymphoblastic leukaemia (ALL), children sometimes exhibit neurological disturbances.
  • Although multiple drugs are used in addition to methotrexate, the acute neurotoxicity reported in patients is usually attributed to methotrexate.
  • The acute neurotoxicity usually results in stroke-like symptoms such as aphasia, weakness, sensory deficits, ataxia and seizures.
  • The paper presents two patients, aged 9 and 15 years respectively, who exhibited acute neurotoxicity--methotrexate encephalopathy during ALL treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. Neurotoxicity Syndromes / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594068.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


60. Ng MH, Lau KM, Hawkins BR, Chik KW, Chan NP, Wong WS, Tsang KS, Shing MM, Li CK: HLA-B67 may be a male-specific HLA marker of susceptibility to relapsed childhood ALL in Hong Kong Chinese and HLA-A33 or HLA-B17 signifies a higher presentation leukocytosis: A retrospective analysis on 53 transplant candidates (1989-2003). Ann Hematol; 2006 Aug;85(8):535-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-B67 may be a male-specific HLA marker of susceptibility to relapsed childhood ALL in Hong Kong Chinese and HLA-A33 or HLA-B17 signifies a higher presentation leukocytosis: A retrospective analysis on 53 transplant candidates (1989-2003).
  • We performed a retrospective analysis on the human leukocyte antigen (HLA) data of 53 consecutive Chinese patients with high-risk childhood acute lymphoblastic leukemia (ALL) diagnosed from 1989 to 2003.
  • Taken together, our findings support the involvement of HLA in Chinese high-risk childhood ALL.
  • [MeSH-major] Biomarkers, Tumor / blood. Disease Susceptibility / blood. HLA-A Antigens / blood. HLA-B Antigens / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710717.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA-A Antigens; 0 / HLA-A*33 antigen; 0 / HLA-B Antigens; 0 / HLA-B17 antigen; 0 / HLA-B67 antigen
  •  go-up   go-down


61. Kitszel A, Krawczuk-Rybak M: Are elevated serum levels of IGFBP-2 after intensive chemotherapy of childhood acute lymphoblastic leukemia a risk factor of relapse? Adv Med Sci; 2007;52:147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are elevated serum levels of IGFBP-2 after intensive chemotherapy of childhood acute lymphoblastic leukemia a risk factor of relapse?
  • INTRODUCTION: In the study we investigated the association between IGFs, their binding proteins and pathogenesis as well as prognostic factors of relapse of childhood ALL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gene Expression Regulation, Leukemic. Insulin-Like Growth Factor Binding Protein 2 / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


62. Stiller CA, Kroll ME, Boyle PJ, Feng Z: Population mixing, socioeconomic status and incidence of childhood acute lymphoblastic leukaemia in England and Wales: analysis by census ward. Br J Cancer; 2008 Mar 11;98(5):1006-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population mixing, socioeconomic status and incidence of childhood acute lymphoblastic leukaemia in England and Wales: analysis by census ward.
  • In this population-based study of acute lymphoblastic leukaemia (ALL) diagnosed among children aged under 15 years in England and Wales during 1986-1995, we analysed incidence at census ward level in relation to a range of variables from the 1991 census, which could be relevant to theories of infectious aetiology.
  • The apparent specificity to the young childhood age group suggests that these associations are particularly marked for precursor B-cell ALL, with the disease more likely to occur when delayed exposure to infection leads to increased immunological stress, as predicted by Greaves.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):483-90 [11519756.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1411-3 [11986772.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):2033-40 [12376209.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):695-8 [12618876.001]
  • [Cites] Am J Epidemiol. 2003 Aug 15;158(4):328-36 [12915498.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Lancet. 1990 Sep 8;336(8715):577-82 [1975376.001]
  • [Cites] J Public Health Med. 1990;12(2):109-17 [2223195.001]
  • [Cites] Lancet. 1990 Dec 15;336(8729):1461-5 [1979091.001]
  • [Cites] BMJ. 1991 Nov 30;303(6814):1357-62 [1760600.001]
  • [Cites] BMJ. 1994 Nov 5;309(6963):1197-202 [7987150.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] BMJ. 1995 Mar 25;310(6982):763-8 [7711579.001]
  • [Cites] BMJ. 1996 Nov 23;313(7068):1297-300 [8942689.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):239-45 [9134248.001]
  • [Cites] Br J Cancer. 1997;76(12):1539-45 [9413937.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):587-91 [9758111.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):30-3 [10408689.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):144-51 [10487626.001]
  • [Cites] Public Health Rep. 1965 Jul;80:573-8 [14310581.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2084-8 [15886703.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):526-31 [15951671.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):140-4 [17533404.001]
  • [CommentIn] Br J Cancer. 2008 Oct 7;99(7):1194; author reply 1191-3 [18827825.001]
  • (PMID = 18253115.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2266854
  •  go-up   go-down


63. Porto L, Kieslich M, Schwabe D, Yan B, Zanella FE, Lanfermann H: Central nervous system lymphoma in children. Pediatr Hematol Oncol; 2005 Apr-May;22(3):235-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper describes the rare MR and CT features of central nervous system (CNS) lymphoma in immunocompetent children and in survivors of childhood acute lymphoblastic leukemia (ALL) and discusses the causative role of cranial irradiation and/or leukoencephalopathy preceding central nervous system (CNS) lymphoma in survivors of childhood leukemia.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020108.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol; 2010 Oct;11(10):950-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
  • Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children with acute lymphoblastic leukaemia (ALL).
  • We aimed to establish the long-term effect of dexrazoxane on the subclinical state of cardiac health in survivors of childhood high-risk ALL 5 years after completion of doxorubicin treatment.

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Heart. 2008 Apr;94(4):525-33 [18347383.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(2):CD003917 [18425895.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3777-84 [18669466.001]
  • [Cites] Am J Cardiol. 2008 Sep 15;102(6):761-6 [18774003.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7 [19018683.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):23-35 [19072983.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2328-38 [19332714.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):243-51 [19020877.001]
  • [Cites] Cardiovasc Toxicol. 2009 Jun;9(2):64-9 [19484391.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] J Am Coll Cardiol. 2009 Aug 4;54(6):491-8 [19643307.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):792-802 [19623174.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(17):3027-34 [19744853.001]
  • [Cites] BMJ. 2009;339:b4606 [19996459.001]
  • [Cites] Curr Opin Pediatr. 2009 Oct;21(5):585-93 [19584723.001]
  • [Cites] Leukemia. 2010 Feb;24(2):371-82 [20010620.001]
  • [Cites] Leukemia. 2010 Feb;24(2):406-18 [20010621.001]
  • [Cites] Leukemia. 2010 Feb;24(2):265-84 [20010625.001]
  • [Cites] Leukemia. 2010 Feb;24(2):309-19 [20016528.001]
  • [Cites] Leukemia. 2010 Feb;24(2):285-97 [20016531.001]
  • [Cites] Leukemia. 2010 Feb;24(2):255-64 [20016536.001]
  • [Cites] Leukemia. 2010 Feb;24(2):335-44 [20016539.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1276-81 [20142585.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1308-15 [20142603.001]
  • [Cites] Toxicology. 2010 Apr 11;270(2-3):92-8 [20132857.001]
  • [Cites] J Am Soc Echocardiogr. 2010 May;23(5):465-95; quiz 576-7 [20451803.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jul;66(2):303-14 [19915844.001]
  • [Cites] JAMA. 2010 Jul 14;304(2):172-9 [20628130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2013-22 [20647396.001]
  • [Cites] J Korean Med Sci. 2010 Sep;25(9):1336-42 [20808678.001]
  • [Cites] Physiol Res. 2010;59(5):831-6 [20406046.001]
  • [Cites] J Am Coll Cardiol. 2011 Jan 4;57(1):76-85 [21185505.001]
  • [Cites] JAMA. 2007 Jun 27;297(24):2705-15 [17595271.001]
  • [Cites] Br J Pharmacol. 2007 Jul;151(6):771-8 [17519947.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3179; author reply 3180 [17634500.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4477-89 [17906209.001]
  • [Cites] Pathol Oncol Res. 2007;13(3):249-53 [17922055.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Nov;275(2):1011-8 [7473127.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):328-31 [8636739.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1544-52 [9193351.001]
  • [Cites] Circulation. 1997 Oct 21;96(8):2641-8 [9355905.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):545-50 [9469339.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):818-24 [10071272.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2629-36 [15837978.001]
  • [Cites] Pediatrics. 2005 Jun;115(6):1613-22 [15930224.001]
  • [Cites] J Appl Physiol (1985). 2005 Aug;99(2):445-57 [15557009.001]
  • [Cites] Am Heart J. 2005 Sep;150(3):439-47 [16169321.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):872-3 [16206201.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):561-78 [16351632.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):614-22 [16423847.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):493-500 [17290056.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):668-75 [17320563.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2237-43 [10561281.001]
  • [Cites] J Am Coll Cardiol. 2000 Mar 1;35(3):569-82 [10716457.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Circulation. 2000 Sep 26;102(13):1542-8 [11182983.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3173-81 [11432883.001]
  • [Cites] Circulation. 2001 Jul 17;104(3):310-6 [11457750.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Oct;48(4):297-304 [11710630.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Biometrics. 2002 Sep;58(3):621-30 [12229997.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4517-22 [12454107.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1074-81 [12637473.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Circulation. 2004 Jun 8;109(22):2749-54 [15148277.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):145-53 [15247354.001]
  • [Cites] Pharmacology. 1983;26(4):210-20 [6844396.001]
  • [Cites] Circulation. 1990 Apr;81(4):1161-72 [2138525.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] J Am Coll Cardiol. 1992 Mar 1;19(3):619-29 [1538019.001]
  • [Cites] J Clin Oncol. 1992 May;10(5):810-7 [1569453.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):477-9 [8341214.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] Expert Opin Pharmacother. 2007 Jun;8(8):1039-58 [17516870.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4689-90; author reply 4690-1 [17925567.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4707-13 [17947717.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1106-11 [18309945.001]
  • (PMID = 20850381.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00165087
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD052104; United States / NHLBI NIH HHS / HL / HL078522; United States / NHLBI NIH HHS / HL / HL095127; United States / NHLBI NIH HHS / HL / R01 HL087000; United States / NHLBI NIH HHS / HL / HL094100; United States / NHLBI NIH HHS / HL / F31 HL094100; United States / NICHD NIH HHS / HD / HD052102; United States / NHLBI NIH HHS / HL / HL053392; United States / NHLBI NIH HHS / HL / HL087000; United States / NCI NIH HHS / CA / R01 CA127642; United States / NHLBI NIH HHS / HL / HL079233; United States / NHLBI NIH HHS / HL / HL007188; United States / NHLBI NIH HHS / HL / HL087708; United States / NCI NIH HHS / CA / CA068484; United States / NHLBI NIH HHS / HL / R01 HL095127; United States / NHLBI NIH HHS / HL / R01 HL078522; United States / NIAID NIH HHS / AI / AI50274; United States / NICHD NIH HHS / HD / U01 HD052102; United States / NHLBI NIH HHS / HL / R13 HL087708; United States / NHLBI NIH HHS / HL / K30 HL004537; United States / NHLBI NIH HHS / HL / T32 HL007188; United States / NICHD NIH HHS / HD / HD80002; United States / NIAID NIH HHS / AI / U01 AI050274; United States / NICHD NIH HHS / HD / HD052104; United States / NCI NIH HHS / CA / CA127642; United States / NCI NIH HHS / CA / P01 CA068484; United States / NHLBI NIH HHS / HL / HL072705; United States / NHLBI NIH HHS / HL / R01 HL053392; United States / NHLBI NIH HHS / HL / HL004537; United States / NHLBI NIH HHS / HL / R01 HL072705
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers; 0 / Cardiovascular Agents; 0 / Troponin T; 5AR83PR647 / Razoxane; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS483981; NLM/ PMC3756093
  •  go-up   go-down


65. Gustafsson B, Angelini S, Sander B, Christensson B, Hemminki K, Kumar R: Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia; 2005 Feb;19(2):310-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia.
  • [MeSH-major] Genes, ras. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins B-raf / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2008 Aug;22(8):1619-21 [18273045.001]
  • (PMID = 15538400.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


66. Meeske KA, Siegel SE, Globe DR, Mack WJ, Bernstein L: Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol; 2005 Aug 20;23(24):5501-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and correlates of fatigue in long-term survivors of childhood leukemia.
  • PURPOSE: To estimate the prevalence of fatigue, identify the factors associated with fatigue, and to explore the relationship between fatigue and quality of life (QOL) in long-term survivors of childhood acute lymphoblastic leukemia (ALL).
  • CONCLUSION: Some survivors of childhood ALL experience fatigue many years after treatment.
  • [MeSH-major] Fatigue / epidemiology. Fatigue / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Quality of Life. Survivors

  • MedlinePlus Health Information. consumer health - Fatigue.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110010.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30 CA14089-25
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


67. Mejstrikova E, Volejnikova J, Fronkova E, Zdrahalova K, Kalina T, Sterba J, Jabali Y, Mihal V, Blazek B, Cerna Z, Prochazkova D, Hak J, Zemanova Z, Jarosova M, Oltova A, Sedlacek P, Schwarz J, Zuna J, Trka J, Stary J, Hrusak O: Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica; 2010 Jun;95(6):928-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.
  • BACKGROUND: Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma.
  • DESIGN AND METHODS: Simple immunophenotypic criteria were used to classify all cases of childhood acute leukemia in order to provide therapy directed against acute lymphoblastic leukemia or acute myeloid leukemia.
  • Prognosis, genotype and immunoglobulin/T-cell receptor gene rearrangement status were analyzed.
  • RESULTS: The incidences of MPAL were 28/582 and 4/107 for children treated with acute lymphoblastic leukemia and acute myeloid leukemia regimens, respectively.
  • In immunophenotypic principal component analysis, MPAL treated as T-cell acute lymphoblastic leukemia clustered between cases of non-mixed T-cell acute lymphoblastic leukemia and acute myeloid leukemia, while other MPAL cases were included in the respective non-mixed B-cell progenitor acute lymphoblastic leukemia or acute myeloid leukemia clusters.
  • Analogously, immunoglobulin/T-cell receptor gene rearrangements followed the expected pattern in patients treated as having acute myeloid leukemia (non-rearranged, 4/4) or as having B-cell progenitor acute lymphoblastic leukemia (rearranged, 20/20), but were missing in 3/5 analyzed cases of MPAL treated as having T-cell acute lymphobastic leukemia.
  • In patients who received acute lymphoblastic leukemia treatment, the 5-year event-free survival of the MPAL cases was worse than that of the non-mixed cases (53+/-10% and 76+/-2% at 5 years, respectively, P=0.0075), with a more pronounced difference among B lineage cases.
  • The small numbers of MPAL cases treated as T-cell acute lymphoblastic leukemia or as acute myeloid leukemia hampered separate statistics.
  • In B lineage leukemia, MPAL confers poorer prognosis.
  • However, our data do not justify a preferential use of current acute myeloid leukemia-based therapy in MPAL.
  • [MeSH-major] Immunophenotyping. Leukemia / diagnosis. Leukemia / therapy. Phenotype
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Follow-Up Studies. Humans. Infant. Infant, Newborn. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Receptors, Antigen, T-Cell / immunology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Jun;19(6):1092-4 [15830012.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2495-500 [16081821.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • [Cites] Leukemia. 2006 Mar;20(3):410-6 [16424874.001]
  • [Cites] Leukemia. 2006 Apr;20(4):620-6 [16437134.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4508-13 [16493009.001]
  • [Cites] Curr Opin Pediatr. 2007 Feb;19(1):1-8 [17224655.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2264-70 [17611554.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):977-83 [18281529.001]
  • [Cites] Blood. 2009 May 21;113(21):5083-9 [19131545.001]
  • [Cites] Haematologica. 2009 Jul;94(7):919-27 [19454497.001]
  • [Cites] Am J Clin Pathol. 2009 Aug;132(2):182-5; quiz 306 [19605811.001]
  • [Cites] Pediatr Blood Cancer. 2010 Jan;54(1):62-70 [19760767.001]
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):757-62 [11380467.001]
  • [Cites] Leukemia. 2002 Mar;16(3):368-75 [11896540.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1233-58 [12094248.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):95-6 [12764763.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):533-9 [12717433.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):524-7 [12847212.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2149-56 [14576730.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):88-9 [15325104.001]
  • [Cites] Haematologica. 1991 May-Jun;76(3):215-25 [1743592.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Am J Hematol. 1996 Feb;51(2):147-51 [8579056.001]
  • [Cites] Haematologica. 1997 Jan-Feb;82(1):64-6 [9107085.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):101-6 [9359509.001]
  • [Cites] Blood. 1998 Jul 15;92(2):596-9 [9657760.001]
  • [Cites] Leukemia. 1999 Feb;13(2):196-205 [10025893.001]
  • [Cites] Haematologica. 1999 Aug;84(8):699-706 [10457405.001]
  • [Cites] Leuk Res. 2005 Jun;29(6):633-9 [15863202.001]
  • [Cites] BMC Cancer. 2005;5:38 [15826304.001]
  • (PMID = 20145275.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Other-IDs] NLM/ PMC2878790
  •  go-up   go-down


68. Rubin J, Frost BM, Arvidson J, Wide K, Gustafsson-Jernberg A, Gustafsson B: Intrathecal chemoprophylaxis after HSCT in children. Pediatr Transplant; 2008 Dec;12(8):889-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our study did not demonstrate a protective effect of i.t. therapy indicating that post-HSCT i.t. therapy may only be of limited use in the treatment of acute childhood leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822104.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


69. Richards NG, Kilberg MS: Asparagine synthetase chemotherapy. Annu Rev Biochem; 2006;75:629-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modern clinical treatments of childhood acute lymphoblastic leukemia (ALL) employ enzyme-based methods for depletion of blood asparagine in combination with standard chemotherapeutic agents.
  • Though the precise molecular mechanisms that result in the appearance of drug resistance are the subject of active study, potent ASNS inhibitors may have clinical utility in treating asparaginase-resistant forms of childhood ALL.
  • This review provides an overview of recent developments in our understanding of (a) the structure and catalytic mechanism of ASNS, and (b) the role that ASNS may play in the onset of drug-resistant childhood ALL.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASPARAGINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7975-9 [10713115.001]
  • [Cites] Biochemistry. 2000 May 23;39(20):6003-11 [10821672.001]
  • [Cites] Plant Physiol. 2000 Jun;123(2):725-32 [10859202.001]
  • [Cites] Annu Rev Biochem. 1999;68:1015-68 [10872471.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1094-9 [10910927.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):26976-85 [10856289.001]
  • [Cites] Bioorg Med Chem Lett. 2000 Aug 21;10(16):1871-4 [10969988.001]
  • [Cites] Curr Opin Struct Biol. 2000 Aug;10(4):401-4 [10981625.001]
  • [Cites] Annu Rev Biochem. 2000;69:617-50 [10966471.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Aug;9(8):1767-75 [11060775.001]
  • [Cites] J Org Chem. 2000 Dec 1;65(24):8229-38 [11101378.001]
  • [Cites] Protein Sci. 2000 Dec;9(12):2329-37 [11206054.001]
  • [Cites] Biochemistry. 2001 Jun 12;40(23):6795-804 [11389593.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4347-68 [11390663.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):321-8 [11415466.001]
  • [Cites] Nat Struct Biol. 2001 Aug;8(8):684-9 [11473258.001]
  • [Cites] Biochem J. 2001 Aug 15;358(Pt 1):59-67 [11485552.001]
  • [Cites] Biochemistry. 2001 Sep 18;40(37):11168-75 [11551215.001]
  • [Cites] J Mol Biol. 2001 Nov 9;313(5):1093-102 [11700065.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47387-93 [11584022.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48100-7 [11677247.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Annu Rev Biochem. 2001;70:149-80 [11395405.001]
  • [Cites] Annu Rev Biochem. 2001;70:209-46 [11395407.001]
  • [Cites] Int J Biochem. 1980;11(6):519-39 [6103827.001]
  • [Cites] Annu Rev Biochem. 1980;49:877-919 [6250450.001]
  • [Cites] Cancer Res. 1981 Aug;41(8):3104-6 [6113889.001]
  • [Cites] Biochemistry. 1981 Dec 8;20(25):7226-32 [6119111.001]
  • [Cites] Anal Biochem. 1983 Apr 1;130(1):134-45 [6688159.001]
  • [Cites] Arch Biochem Biophys. 1985 Mar;237(2):335-46 [2858178.001]
  • [Cites] Arch Biochem Biophys. 1985 May 1;238(2):410-7 [2859838.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1914-9 [2868008.001]
  • [Cites] Biochemistry. 1985 Feb 26;24(5):1104-10 [2869778.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1321-3 [3464352.001]
  • [Cites] Am J Clin Oncol. 1986 Oct;9(5):411-5 [3465228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Mar;84(6):1565-9 [3470743.001]
  • [Cites] J Biol Chem. 1987 Aug 25;262(24):11565-70 [2887559.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301 [3281418.001]
  • [Cites] Leukemia. 1989 Apr;3(4):294-7 [2564453.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2350-9 [2569668.001]
  • [Cites] Biochem Int. 1989 Mar;18(3):661-6 [2569873.001]
  • [Cites] Biochemistry. 1999 Dec 7;38(49):16146-57 [10587437.001]
  • [Cites] Protein Sci. 1999 Nov;8(11):2424-7 [10595545.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36498-504 [10593947.001]
  • [Cites] Bioorg Med Chem. 1999 Nov;7(11):2473-85 [10632057.001]
  • [Cites] Genetics. 2000 Feb;154(2):787-801 [10655230.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 1):C1691-9 [9176161.001]
  • [Cites] Trends Biochem Sci. 1997 Jun;22(6):211-6 [9204708.001]
  • [Cites] Biochemistry. 1997 Aug 19;36(33):10168-77 [9254614.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):21661-4 [9268289.001]
  • [Cites] Nat Prod Rep. 1997 Aug;14(4):309-33 [9281835.001]
  • [Cites] Biochemistry. 1997 Sep 16;36(37):11061-8 [9333323.001]
  • [Cites] Nat Struct Biol. 1998 Jan;5(1):15-9 [9437423.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:87-144 [9559052.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:145-98 [9559053.001]
  • [Cites] Cell Mol Life Sci. 1998 Mar;54(3):205-22 [9575335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9082-6 [9689037.001]
  • [Cites] Biochemistry. 1998 Sep 22;37(38):13230-8 [9748330.001]
  • [Cites] Annu Rev Biochem. 1998;67:693-720 [9759501.001]
  • [Cites] Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113 [9768345.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):31691-701 [9822630.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Biochem J. 1999 Apr 1;339 ( Pt 1):135-41 [10085237.001]
  • [Cites] Biochem J. 1999 Apr 1;339 ( Pt 1):151-8 [10085239.001]
  • [Cites] Chem Biol. 1999 Apr;6(4):R91-R105 [10099128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9479-84 [10449718.001]
  • [Cites] Acc Chem Res. 2003 Jul;36(7):539-48 [12859215.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302 [14499708.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38402-12 [12881527.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2003;32:335-73 [12574069.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):40996-1002 [12890666.001]
  • [Cites] Biochemistry. 2004 Jan 13;43(1):9-18 [14705926.001]
  • [Cites] Leukemia. 2004 Mar;18(3):434-41 [14724653.001]
  • [Cites] Bioorg Chem. 2004 Apr;32(2):63-75 [14990305.001]
  • [Cites] Curr Top Med Chem. 2004;4(7):653-69 [15032680.001]
  • [Cites] Cell Mol Life Sci. 2004 Mar;61(6):669-81 [15052410.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Biochemistry. 2004 Jun 1;43(21):6447-63 [15157079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10000-5 [15220480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11269-74 [15277680.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Biochemistry. 2004 Aug 17;43(32):10328-42 [15301531.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):27-33 [15479734.001]
  • [Cites] J Biol Chem. 1968 Jan 25;243(2):376-80 [4295091.001]
  • [Cites] Science. 1968 May 3;160(3827):533-5 [5689413.001]
  • [Cites] Biochem Biophys Res Commun. 1968 Apr 5;31(1):43-7 [4869945.001]
  • [Cites] Biochemistry. 1969 Jun;8(6):2681-5 [5799144.001]
  • [Cites] J Biol Chem. 1969 Aug 10;244(15):4112-21 [4895361.001]
  • [Cites] J Biol Chem. 1989 Sep 15;264(26):15494-500 [2768274.001]
  • [Cites] Biochemistry. 1990 Jan 16;29(2):366-72 [1967948.001]
  • [Cites] Somat Cell Mol Genet. 1990 Jan;16(1):59-65 [1968681.001]
  • [Cites] Nucleic Acids Res. 1990 Jun 25;18(12):3509-13 [1972978.001]
  • [Cites] Protein Eng. 1990 Aug;3(8):739-44 [1977158.001]
  • [Cites] Biochemistry. 1991 Jun 25;30(25):6135-41 [1676298.001]
  • [Cites] Mol Cell Biol. 1991 Dec;11(12):6059-66 [1682798.001]
  • [Cites] J Biol Chem. 1992 Jan 5;267(1):144-9 [1346128.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 28;183(1):265-72 [1543496.001]
  • [Cites] Arch Biochem Biophys. 1992 May 15;295(1):120-5 [1349469.001]
  • [Cites] Biosci Biotechnol Biochem. 1992 Mar;56(3):376-9 [1369484.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 May;14(2):136-9 [1530118.001]
  • [Cites] Protein Eng. 1992 Apr;5(3):279-83 [1357656.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1993;66:203-309 [8430515.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3202-12 [8098842.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16771-80 [8102140.001]
  • [Cites] Biochemistry. 1994 Jan 25;33(3):675-81 [7904828.001]
  • [Cites] J Biol Chem. 1994 Mar 11;269(10):7450-7 [7907328.001]
  • [Cites] J Biol Chem. 1994 Sep 30;269(39):24304-9 [7929087.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26789-95 [7929415.001]
  • [Cites] Nature. 1995 Jan 19;373(6511):264-8 [7816145.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16585-91 [11867623.001]
  • [Cites] J Org Chem. 2002 May 17;67(10):3290-300 [12003538.001]
  • [Cites] J Org Chem. 2002 Jun 14;67(12):4372-5 [12054978.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24120-7 [11960987.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24579-83 [11967268.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jan;1(1):26-36 [12119606.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):161-80; discussion 200-2 [12196214.001]
  • [Cites] Cancer. 1970 Feb;25(2):306-20 [4905155.001]
  • [Cites] Annu Rev Pharmacol. 1970;10:421-40 [4911021.001]
  • [Cites] Ann Intern Med. 1971 Jun;74(6):893-901 [5281051.001]
  • [Cites] Cancer. 1971 Oct;28(4):819-24 [5286444.001]
  • [Cites] Transplantation. 1971 Nov;12(5):368-76 [4948688.001]
  • [Cites] Cancer. 1972 Aug;30(2):376-81 [4559405.001]
  • [Cites] J Biol Chem. 1973 Jun 10;248(11):3997-4002 [4145324.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1973;39:91-183 [4355768.001]
  • [Cites] Enzyme. 1975;19(5-6):314-28 [237754.001]
  • [Cites] J Med Chem. 1975 Sep;18(9):888-91 [240024.001]
  • [Cites] Cancer Treat Rep. 1976 Oct;60(10):1493-557 [14784.001]
  • [Cites] Cancer. 1979 Mar;43(3):1089-94 [284840.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3893-6 [383278.001]
  • [Cites] Methods Enzymol. 1980;64:47-59 [7374457.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6566-74 [10490596.001]
  • [Cites] Nat Rev Drug Discov. 2004 Nov;3(11):935-49 [15520816.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50829-39 [15385533.001]
  • [Cites] Nature. 2004 Dec 16;432(7019):855-61 [15602551.001]
  • [Cites] Med Res Rev. 2005 Mar;25(2):186-228 [15478125.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Mass Spectrom Rev. 2005 Mar-Apr;24(2):168-200 [15389855.001]
  • [Cites] Nat Rev Drug Discov. 2005 Apr;4(4):345-50 [15789121.001]
  • [Cites] Plant Physiol. 2005 Apr;137(4):1487 [15824288.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4223-5 [15718422.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(19):6681-8 [12215525.001]
  • [Cites] Nat Rev Drug Discov. 2002 Nov;1(11):882-94 [12415248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14752-7 [12409610.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7639-44 [12496246.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2743-7 [12433682.001]
  • [Cites] Arch Biochem Biophys. 2003 May 1;413(1):23-31 [12706338.001]
  • [Cites] Appl Microbiol Biotechnol. 2003 May;61(4):278-88 [12743756.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):603-9 [12628003.001]
  • [Cites] Org Lett. 2003 Jun 12;5(12):2033-6 [12790521.001]
  • [Cites] Biochemistry. 2003 Jun 17;42(23):7013-22 [12795596.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):22964-71 [12684518.001]
  • [Cites] Biochem J. 1994 Dec 15;304 ( Pt 3):745-50 [7818476.001]
  • [Cites] Blood. 1995 Feb 1;85(3):751-6 [7833478.001]
  • [Cites] Proteins. 1994 Dec;20(4):347-55 [7731953.001]
  • [Cites] Methods Enzymol. 1995;249:284-312 [7791615.001]
  • [Cites] Nature. 1995 Nov 23;378(6555):416-9 [7477383.001]
  • [Cites] Nat Struct Biol. 1995 Dec;2(12):1102-8 [8846222.001]
  • [Cites] Nat Struct Biol. 1996 Jan;3(1):74-86 [8548458.001]
  • [Cites] J Bacteriol. 1996 Apr;178(8):2459-61 [8636057.001]
  • [Cites] J Med Chem. 1996 Jun 7;39(12):2367-78 [8691431.001]
  • [Cites] Med Res Rev. 1996 Jan;16(1):3-50 [8788213.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 Jan;25(1):11-26 [9134309.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12384-92 [9139684.001]
  • [Cites] Annu Rev Biochem. 2005;74:739-89 [15952902.001]
  • [Cites] Annu Rev Nutr. 2005;25:59-85 [16011459.001]
  • [Cites] Arch Biochem Biophys. 2005 Aug 1;440(1):18-27 [16023613.001]
  • [Cites] Nat Rev Drug Discov. 2005 Aug;4(8):649-63 [16056391.001]
  • (PMID = 16756505.001).
  • [ISSN] 0066-4154
  • [Journal-full-title] Annual review of biochemistry
  • [ISO-abbreviation] Annu. Rev. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA09126; United States / NIDDK NIH HHS / DK / DK52064; United States / NCI NIH HHS / CA / T32 CA009126; United States / NIDDK NIH HHS / DK / R01 DK052064; United States / NCI NIH HHS / CA / CA107437; United States / NCI NIH HHS / CA / R21 CA107437
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 7006-34-0 / Asparagine; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  • [Number-of-references] 187
  • [Other-IDs] NLM/ NIHMS447419; NLM/ PMC3587692
  •  go-up   go-down


70. Stary J, Jabali Y, Trka J, Hrusak O, Gajdos P, Hrstkova H, Sterba J, Blazek B, Hak J, Prochazkova D, Cerna Z, Smisek P, Sedlacek P, Vavra V, Mihal V, Hrodek O, Czech Pediatric Hematology working group: Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia; 2010 Feb;24(2):425-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


71. Jiang H, Gu LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J: [Asparagine synthetase activity in pediatric acute lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug;8(4):272-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asparagine synthetase activity in pediatric acute lymphoblastic leukemia].
  • OBJECTIVE: To study the cellular activity of asparagine synthetase in different types of childhood acute lymphoblastic leukemia (ALL).
  • METHODS: The cellular activity of asparagine synthetase was detected by HPLC-FLD and Protein measurement in 28 ALL children (7 cases of T-ALL and 21 cases of B-lymphoid lineage ALL) before chemotherapy.
  • RESULTS: The asparagines synthetase activity levels in T-ALL children were significantly higher than those of the B-lymphoid lineage ALL patients, with the median activity level of 9.3 nM Asn/mg protein/hr vs 5.2 nM Asn/mg protein/hr (P < 0.05).
  • The distribution of the asparagine synthetase activity demonstrated a polymorphism in either T-ALL or B-lymphoid lineage ALL patients.
  • The asparagines synthetase activity levels in T-ALL are significantly higher than in B-lymphoid lineage ALL.
  • [MeSH-major] Aspartate-Ammonia Ligase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923354.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / TEL-AML1 fusion protein; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


72. Chen FX, Cui YQ, Wu ZL, Ye TZ, Lai YH, Zou YW, Lu CY, Guan JM, Wei FG, Zhang H: [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2005 Feb;26(2):100-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
  • OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Asparaginase / pharmacokinetics. Asparagine / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921627.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


73. Gustafsson B, Jernberg AG, Priftakis P, Bogdanovic G: No CMV DNA in Guthrie cards from children who later developed ALL. Pediatr Hematol Oncol; 2006 Apr-May;23(3):199-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An association of a viral infection in utero and development of acute lymphoblastic leukemia (ALL) has been suggested.
  • The results show that prenatal CMV infection does not seem to be associated with later development of childhood ALL.
  • [MeSH-major] Cytomegalovirus / isolation & purification. Cytomegalovirus Infections / congenital. DNA, Viral / blood. Neonatal Screening / instrumentation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Viremia / congenital

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • MedlinePlus Health Information. consumer health - Newborn Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517536.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


74. Swaminathan R, Rama R, Shanta V: Childhood cancers in Chennai, India, 1990-2001: incidence and survival. Int J Cancer; 2008 Jun 1;122(11):2607-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood cancers in Chennai, India, 1990-2001: incidence and survival.
  • Childhood cancers (age at diagnosis: 0-14 years) comprise a variety of malignancies, with incidence varying worldwide by age, sex, ethnicity and geography, that provide insights into cancer etiology.
  • A total of 1,334 childhood cancers registered in population-based cancer registry, Chennai, India, during 1990-2001 and categorized by International Classification of Childhood Cancer norms formed the study material.
  • The age-standardized rates for all childhood cancers together were 127 per million boys and 88 per million girls.
  • The top 5 childhood cancers were the same among boys and girls: leukemias, lymphomas, central nervous system neoplasms, retinoblastomas and renal tumors.
  • The highest 5-year absolute survival was observed in Hodgkin's disease (65%) followed by Wilm's tumor (64%), retinoblastomas (48%), non-Hodgkin's lymphomas (47%), osteosarcomas (44%), acute lymphoid leukemia and astrocytoma (39%).
  • Multifactorial analysis of age at diagnosis and sex showed no differences in the risk of dying for all childhood cancers.
  • Completeness of treatment and type of hospital combination emerged as a prognostic factor for survival for all childhood cancers together (p < 0.001), acute lymphoid leukemia (p < 0.001) and non-Hodgkin's lymphoma (p = 0.04).
  • A Childhood Cancer Registry with high-resolution data collection is advocated for in-depth analysis of variation in incidence and survival.
  • [MeSH-minor] Actuarial Analysis. Adolescent. Age Distribution. Central Nervous System Neoplasms / epidemiology. Child. Child, Preschool. Female. Humans. Incidence. India / epidemiology. Infant. Kidney Neoplasms / epidemiology. Leukemia / epidemiology. Lymphoma / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Multivariate Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Prognosis. Proportional Hazards Models. Registries. Retinoblastoma / epidemiology. Survival Analysis. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18324630.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Hunger SP, Sung L, Howard SC: Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal. Pediatr Blood Cancer; 2009 May;52(5):559-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal.
  • Cure rates for children with acute lymphoblastic leukemia (ALL) are 80-85% in high-income countries (HICs) in North America and Western Europe.
  • Over the past several decades partnerships ("twinning") between HIC and LIC pediatric oncology programs have led to major improvements in outcome for children with ALL in some LICs, often by developing time and resource intensive relationships that allow LIC centers to treat children with regimens similar or identical to those used in HICs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Developing Countries / economics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / economics


76. Szegedi I, Katona K, Horváth A, Molnár A, Aradi J, Kiss C: Bcl-2 antisense oligonucleotide inhibits the proliferation of childhood leukemia/lymphoma cells of the B-cell lineage. Pathol Oncol Res; 2008 Sep;14(3):275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 antisense oligonucleotide inhibits the proliferation of childhood leukemia/lymphoma cells of the B-cell lineage.
  • An 18-mer phosphorothioate bcl-2 antisense oligonucleotide (ASO) inhibited colony formation of three B-cell leukemia/lymphoma cell lines in a dose dependent manner in the range of 0.125-0.5 micromol/l.
  • A decrease in BCL-2 protein and apoptotic DNA fragmentation was detected in the studied cell lines and primary blast cells of two children with acute lymphoblastic leukemia.
  • As far as we know, this is the first report on the effects of bcl-2 ASO on childhood leukemia/lymphoma cell samples.
  • [MeSH-major] B-Lymphocytes / pathology. Cell Proliferation / drug effects. Leukemia / pathology. Lymphoma / pathology. Thionucleotides / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Child. Child, Preschool. DNA Fragmentation. Dose-Response Relationship, Drug. Female. Humans. Male. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] J Natl Cancer Inst. 1987 Feb;78(2):235-42 [3027441.001]
  • [Cites] Cancer Lett. 2001 May 10;166(1):9-15 [11295281.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2001 May;363(5):499-508 [11383710.001]
  • [Cites] Blood. 1994 Jul 15;84(2):595-600 [8025285.001]
  • [Cites] Drugs R D. 2007;8(5):321-34 [17767397.001]
  • [Cites] J Leukoc Biol. 2002 Jul;72(1):83-92 [12101266.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2879-86 [11023525.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):341-3 [15745756.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2000 Sep;80(9):694-7 [11798838.001]
  • [Cites] Curr Opin Oncol. 1995 Nov;7(6):541-6 [8547403.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1999 Jul;21(4):253-5 [11776807.001]
  • [Cites] Lancet. 1997 Apr 19;349(9059):1137-41 [9113013.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6565-70 [2208117.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9087-96 [14663487.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2003 Feb;24(2):71-3 [12697099.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Mar;73(3):910-4 [1062804.001]
  • [Cites] Mol Urol. 2001 Summer;5(2):71-8 [11690551.001]
  • (PMID = 18575824.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Thionucleotides; 85J5ZP6YSL / oblimersen
  •  go-up   go-down


77. Nurmio M, Keros V, Lähteenmäki P, Salmi T, Kallajoki M, Jahnukainen K: Effect of childhood acute lymphoblastic leukemia therapy on spermatogonia populations and future fertility. J Clin Endocrinol Metab; 2009 Jun;94(6):2119-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of childhood acute lymphoblastic leukemia therapy on spermatogonia populations and future fertility.
  • CONTEXT: Isolation of spermatogonial stem cells before potentially sterilizing cancer therapy, followed by transplantation of these cells into the testis after such treatment, may be an effective approach to prevent infertility among prepubertal boys suffering from acute lymphoblastic leukemia (ALL).
  • A key clinical consideration in this context is the timing of biopsy, if collection of spermatogonia could be delayed from diagnosis to the later phase of leukemia treatment, better patient selection could be offered.
  • OBJECTIVE: The objective of the study was to examine the routine testicular biopsy material collected to detect testicular leukemia to evaluate if treatment for leukemia affects numbers and maturation of the spermatogonia during the prepubertal period.
  • OUTCOME MEASURE: Samples were stained immunohistochemically to evaluate the expression of the spermatogonial markers MAGE 4A, OCT4, CD9, and AP2gamma, and of the Sertoli cell marker WT-1.
  • No significant alteration in spermatogonial numbers was associated with testicular leukemia.
  • CONCLUSION: Treatment for childhood leukemia without high-dose cyclophosphamide seldom depletes the spermatogonial stem cell pool totally.
  • [MeSH-major] Cyclophosphamide / adverse effects. Fertility / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sperm Count. Spermatogonia / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318447.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


78. Leclerc GJ, Mou C, Leclerc GM, Mian AM, Barredo JC: Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. Leukemia; 2010 Mar;24(3):552-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
  • Children with acute lymphoblastic leukemia (ALL) diagnosed with resistant phenotypes, and those who relapse, have a dismal prognosis for cure.
  • We demonstrated that histone deacetylase-1 (HDAC1) is recruited by NFY and Sp1 transcription factors to the FPGS promoter in ALL cell lines.
  • Combination treatment with MTX plus SAHA significantly increased cytotoxicity and apoptosis in B- and T-ALL cell lines as compared with each drug alone (CI<or=0.8).
  • Therefore, HDACI-induced FPGS expression increases the accumulation of MTX-PG(3-7) and cytotoxicity in ALL cell lines, which is potentiated by DHFR and TS downregulation.
  • [MeSH-major] Histone Deacetylase Inhibitors / pharmacology. Methotrexate / analogs & derivatives. Peptide Synthases / genetics. Polyglutamic Acid / analogs & derivatives. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CCAAT-Binding Factor / physiology. Cell Line, Tumor. Exons. Gene Expression Regulation, Enzymologic / drug effects. Histone Deacetylase 1 / physiology. Humans. Hydroxamic Acids / administration & dosage. Sp1 Transcription Factor / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2011 Feb;25(2):359-61 [21072050.001]
  • (PMID = 20072153.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098152
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Binding Factor; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / NFYB protein, human; 0 / Sp1 Transcription Factor; 25513-46-6 / Polyglutamic Acid; 58IFB293JI / vorinostat; 82334-40-5 / methotrexate polyglutamate; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 6.3.2.- / Peptide Synthases; EC 6.3.2.17 / folylpolyglutamate synthetase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


79. Kolenova A, Hikkel I, Ilencikova D, Hikkelova M, Sejnova D, Kaiserova E, Cizmar A, Puskacova J, Bubanska E, Oravkinova I, Gencik M: Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience. Neoplasma; 2010;57(6):552-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
  • Acute lymphoblastic leukemia is the most common form of cancer in children.
  • An intense effort has been made to develop methods to determine the degree of minimal residual leukemia cells present in patients considered to be in morphological remission.
  • The MRD monitoring based on real-time quantitative PCR detection of patient-specific immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements is currently considered to be the most reliable tool for MRD-based diagnosis in ALL.
  • A total of 40 patients with BCP-ALL ( B cell precursor ALL) and 4 patients with T ALL were analyzed for Ig/TCR rearrangement.
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, T-Lymphocyte. Genes, Immunoglobulin. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845994.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


80. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K, Peterson C: The association of reduced folate carrier 80G&gt;A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood; 2010 Jun 10;115(23):4671-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number.
  • The reduced folate carrier (RFC) is involved in the transport of methotrexate (MTX) across the cell membrane.
  • The RFC gene (SLC19A1) is located on chromosome 21, and we hypothesized that the RFC80 G>A polymorphism would affect outcome and toxicity in childhood leukemia and that this could interact with chromosome 21 copy number in the leukemic clone.
  • A total of 500 children with acute lymphoblastic leukemia treated according to the common Nordic treatment protocols were included, and we found that the RFC AA variant was associated with a 50% better chance of staying in remission compared with GG or GA variants (P = .046).
  • [MeSH-major] Aneuploidy. Chromosomes, Human, Pair 21 / genetics. Membrane Transport Proteins / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma


81. Abadie C, Bernard F, Netchine I, Sanlaville D, Roque A, Rossignol S, Coupier I: Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation. Eur J Med Genet; 2010 Nov-Dec;53(6):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation.
  • Beckwith-Wiedemann syndrome (BWS) is a rare overgrowth syndrome associated with an increased risk in childhood tumours.
  • We report the case of a 10-year-old patient diagnosed with BWS, harbouring a CDKN1C (p57(KIP2)) mutation, who developed a T-type acute lymphoblastic leukaemia.
  • To our knowledge it is the first report of an acute lymphoblastic leukaemia of T-type in a child with BWS.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / genetics. Cyclin-Dependent Kinase Inhibitor p57 / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20826236.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57
  •  go-up   go-down


82. Papageorgiou AC, Posypanova GA, Andersson CS, Sokolov NN, Krasotkina J: Structural and functional insights into Erwinia carotovora L-asparaginase. FEBS J; 2008 Sep;275(17):4306-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the past 30 years, these enzymes have been used as therapeutic agents in the treatment of acute childhood lymphoblastic leukemia.
  • Erwinia carotovora asparaginase shows decreased glutaminase activity, so it is believed to have fewer side-effects in leukemia therapy.
  • Cytotoxicity measurements revealed that E. carotovora asparaginase is 30 times less toxic than the Escherichia coli enzyme against human leukemia cell lines.
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Binding Sites. Cell Line, Tumor. DNA Primers. Humans. Models, Molecular. Molecular Sequence Data. Protein Conformation. Sequence Homology, Amino Acid

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647344.001).
  • [ISSN] 1742-464X
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 2JK0
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


83. Cowan SA: Denmark decides not to introduce hepatitis B into the childhood vaccination programme. Euro Surveill; 2005;10(11):E051103.3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denmark decides not to introduce hepatitis B into the childhood vaccination programme.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794274.001).
  • [ISSN] 1560-7917
  • [Journal-full-title] Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
  • [ISO-abbreviation] Euro Surveill.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


84. Yoshida Y, Toma Y, Arai M, Higashi R, Kashihara K, Kaizaki Y: [Primitive neuroectodermal tumor arising 8 years after chemotherapy and radiotherapy for acute lymphoblastic leukemia: case report]. No Shinkei Geka; 2005 Jul;33(7):717-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive neuroectodermal tumor arising 8 years after chemotherapy and radiotherapy for acute lymphoblastic leukemia: case report].
  • We report a case of primitive neuroectodermal tumor (PNET) arising 8 years after chemotherapy and radiotherapy for acute lymphoblastic leukemia.
  • A 15-year-old boy with a history of acute lymphoblastic leukemia, at the age of 7, underwent chemotherapy and 14Gy of radiotherapy to the whole brain.
  • This tumor was thought to be a secondary brain tumor arising in this survivor of childhood acute lymphoblastic leukemia and it is a rare complication of successful leukemia treatment.
  • [MeSH-major] Brain Neoplasms / surgery. Cranial Irradiation. Neoplasms, Second Primary. Neuroectodermal Tumors, Primitive / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001813.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Robazzi TC, Barreto JH, Silva LR, Santiago MB, Mendonça N: Osteoarticular manifestations as initial presentation of acute leukemias in children and adolescents in Bahia, Brazil. J Pediatr Hematol Oncol; 2007 Sep;29(9):622-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoarticular manifestations as initial presentation of acute leukemias in children and adolescents in Bahia, Brazil.
  • OBJECTIVE: This study was to determine the prevalence and characteristics of the osteoarticular manifestations on initial clinical presentation of acute leukemias (ALs) on childhood in the state of Bahia, Brazil.
  • RESULTS: Acute lymphocytic leukemia (ALL) was diagnosed in 313 (77.1%) patients and acute myeloid leukemia (AML), in 93 (22.9%) patients, including 241 males (59.4%) and 165 females (40.6%).
  • Prior referral to our center, the most frequent initial diagnosis was anemia (15.8%), leukemia (15.0%), amygdalitis (3.7%), and rheumatic fever (2.7%).
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Osteoarthritis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Brazil. Child. Child, Preschool. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Osteoarthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805037.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Schrappe M: Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. Radiat Prot Dosimetry; 2008;132(2):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
  • Systematic enrollment of children and adolescents with acute lymphoblastic leukaemia (ALL) into clinical trials has allowed the establishment of prognostic parameters derived from initial diagnostic findings.
  • More important, these trials have significantly contributed to the reduction of disease recurrence as much as to the reduction of acute and late side effects.
  • Some problems that are related to the specificity of the parameters used for risk assessment were not overcome: high tumour load by white blood cell count (WBC), age and (rare) cytogenetic subtypes (e.g. t9;22) may characterise a significant proportion of children and adolescents with high-risk ALL.
  • This may facilitate innovative chemotherapy approaches and a more rational use of allogeneic haematopoetic stem cell transplantation.
  • [MeSH-major] Clinical Trials as Topic. Disease Outbreaks / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017727.001).
  • [ISSN] 0144-8420
  • [Journal-full-title] Radiation protection dosimetry
  • [ISO-abbreviation] Radiat Prot Dosimetry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


87. Yang Y, Jin XM, Yan CH, Tian Y, Tang JY, Shen XM: Urinary level of nickel and acute leukaemia in Chinese children. Toxicol Ind Health; 2008 Oct;24(9):603-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary level of nickel and acute leukaemia in Chinese children.
  • However, few studies on urinary 8-OHdG and metals have been conducted in children with acute leukemia.
  • In the present study, urinary Ni and 8-OHdG were examined in 116 children with acute leukaemia (94 acute lymphoid leukaemia [ALL] and 22 acute myeloid leukaemia [AML]) and 51 healthy child controls.
  • Our result showed that urinary Ni in acute leukaemia patients (ALL: 68.40 +/- 133.98, AML: 41.48 +/- 76.31 ng/mg creatinine) was significantly higher than that in controls (62.47 +/- 124.90 vs 17.63 +/- 46.17 ng/mg creatinine, P < 0.05).
  • Moreover, urinary 8-OHdG and urinary Ni showed a weak but significant association with increased risk of childhood leukaemia.
  • The present study suggests that Ni may be an etiologic factor for childhood acute leukaemia by oxidative DNA damage.
  • [MeSH-major] Deoxyguanosine / analogs & derivatives. Leukemia, Myeloid, Acute / urine. Nickel / urine. Precursor Cell Lymphoblastic Leukemia-Lymphoma / urine

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106127.001).
  • [ISSN] 0748-2337
  • [Journal-full-title] Toxicology and industrial health
  • [ISO-abbreviation] Toxicol Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Metals, Heavy; 0 / Metals, Light; 7OV03QG267 / Nickel; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


88. Steiner M, Attarbaschi A, Dworzak M, Strobl H, Pickl W, Kornmüller R, Haas O, Gadner H, Mann G, Austrian Berlin-Frankfurt-Münster Study Group: Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. J Pediatr Hematol Oncol; 2010 Jan;32(1):e4-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia.
  • Rarely, cytochemical MPO reaction may be positive in >or=3% of blasts with clear lymphoblastic morphology.
  • We present 5 patients with cytochemically MPO-positive acute leukemia classified as lymphoblastic by cytomorphology and lymphoblastic (n=3) or biphenotypic (n=2) by immunophenotyping, who entered first-line treatment for lymphoblastic leukemia.
  • The former 3 are in first remission and both with biphenotypic leukemia relapsed with acute myeloid leukemia.
  • The study primarily shows that cytochemical MPO expression in childhood acute leukemia revealing typical lymphoblastic morphology and phenotype does rarely exist.
  • Although a small number of patients studied, cytochemical MPO expression in acute leukemia does not seem to require myeloid leukemia treatment in case of otherwise lymphoblastic cytomorphology and phenotype.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Peroxidase / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


89. Biondi A, Baruchel A, Hunger S, Masera G, Schmiegelow K, Schrappe M, Pui CH: The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia; 2009 Dec;23(12):2318-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.
  • An international childhood acute lymphoblastic leukemia (ALL)working group was formed during the 27th annual meeting of the International Society of Pediatric Oncology in 1995.
  • Since then, 10 workshops have been held to address many issues that help advance treatment outcome of childhood ALL but require international collaboration (Table 1).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 May 15;115(10):2147-54 [19298009.001]
  • [Cites] Leukemia. 2009 Mar;23(3):528-34 [19020543.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6077-84 [19224761.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Leukemia. 2009 Jul;23(7):1264-9 [19212332.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1406-9 [19282835.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] Leukemia. 2010 Feb;24(2):355-70 [20016527.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Feb;47(2):149-58 [17990329.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1496-503 [18349402.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Blood. 2008 May 1;111(9):4477-89 [18285545.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3046-50 [18565891.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Pharmacogenomics. 2008 Nov;9(11):1573-7 [19018710.001]
  • [Cites] Leukemia. 2003 Mar;17(3):547-53 [12646943.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1679-82 [12886264.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] J Infect Dis. 1996 Nov;174 Suppl 3:S320-3 [8896539.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8167-72 [16702559.001]
  • [Cites] Leukemia. 2007 Feb;21(2):288-96 [17183364.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2202-4 [17068151.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2327-30 [17095619.001]
  • [Cites] Lancet. 2007 Apr 7;369(9568):1232 [17416267.001]
  • [Cites] Leukemia. 2009 Jan;23(1):209-12 [18615108.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):125-34 [19138562.001]
  • [Cites] Br J Haematol. 2009 Mar;144(6):930-2 [19120350.001]
  • [Cites] Leukemia. 2009 Mar;23(3):557-64 [18987654.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1073-9 [19212338.001]
  • (PMID = 19890375.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS138520; NLM/ PMC2818074
  •  go-up   go-down


90. Eiser C, Davies H, Jenney M, Glaser A: Mothers' attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children. Child Care Health Dev; 2005 Sep;31(5):517-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mothers' attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children.
  • OBJECTIVES: Survival rates for childhood cancer have improved substantially partly as a result of national and international randomized clinical trials (RCT).
  • [MeSH-major] Mothers / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Randomized Controlled Trials as Topic / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101646.001).
  • [ISSN] 0305-1862
  • [Journal-full-title] Child: care, health and development
  • [ISO-abbreviation] Child Care Health Dev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Satwani P, Sather H, Ozkaynak F, Heerema NA, Schultz KR, Sanders J, Kersey J, Davenport V, Trigg M, Cairo MS: Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report. Biol Blood Marrow Transplant; 2007 Feb;13(2):218-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.
  • The prognosis for childhood acute lymphoblastic leukemia (ALL) has improved dramatically over the past quarter of a century.
  • Despite improvements in the treatment of childhood ALL, relapse still occurs in 20%-30% of patients.
  • The incidence of grade II-IV acute GVHD was 20.7% and the incidence of chronic GVHD was 3.7%.
  • Randomized prospective cooperative group studies are required to establish the role of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in children with UHRF ALL in CR1.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Dec;13(12):2053-8 [10602428.001]
  • [Cites] Blood. 1991 Feb 1;77(3):435-9 [1991160.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2412-8 [11001892.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Leuk Res. 1986;10(4):457-9 [3515055.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):657-63 [2943992.001]
  • [Cites] Blood. 1991 Oct 15;78(8):1923-7 [1912575.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):97-100 [1554802.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • [Cites] Blood. 1992 Aug 15;80(4):1090-3 [1498326.001]
  • [Cites] Lancet. 1992 Sep 5;340(8819):565-8 [1355153.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1289-95 [8413409.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1275-9 [8057661.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1395-404 [10189148.001]
  • [Cites] Br J Haematol. 2005 Apr;129(1):35-44 [15801953.001]
  • [Cites] Blood. 2005 May 1;105(9):3749-56 [15637143.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):635-42 [16112299.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):999-1005 [16338622.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):535-8 [7537528.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3353-4 [7756668.001]
  • [Cites] Bone Marrow Transplant. 1995 Nov;16(5):663-7 [8547863.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):357-63 [8704687.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):365-9 [8704688.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):35-42 [9065717.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1410-4 [9269758.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4243-51 [9373234.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2285-95 [9404706.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1031-6 [9665186.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2730-41 [9763557.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(11):1029-33 [9877263.001]
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):1-6 [9917745.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):445-55 [10080584.001]
  • [Cites] Blood. 1987 Aug;70(2):587-8 [3300815.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):747-53 [2654331.001]
  • [Cites] Blood. 1990 Aug 1;76(3):489-94 [2378982.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):340-7 [10637248.001]
  • (PMID = 17241927.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA013539; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA 13539; United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS17434; NLM/ PMC2731715
  •  go-up   go-down


92. Tissing WJ, Lauten M, Meijerink JP, den Boer ML, Koper JW, Sonneveld P, Pieters R: Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia. Haematologica; 2005 Sep;90(9):1279-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia.
  • In vitro prednisolone resistance is a poor prognostic factor in the treatment of childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / therapeutic use. Receptors, Glucocorticoid / biosynthesis

  • Genetic Alliance. consumer health - Glucocorticoid Resistance.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16154856.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Protein Isoforms; 0 / Receptors, Glucocorticoid; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


93. Wu XD, Li CF, He YL, Yang M, Zhang YM, Feng XQ, Teng ZL, Sun SM, Qian XH: [Analysis of therapeutic effectiveness of Nanfang ALL 99 protocol in childhood acute lymphoblastic leukemia patients]. Zhonghua Er Ke Za Zhi; 2005 Dec;43(12):890-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of therapeutic effectiveness of Nanfang ALL 99 protocol in childhood acute lymphoblastic leukemia patients].
  • OBJECTIVE: With more precise diagnostic criteria and risk classifications, more effective therapy administered in clinical trials, and better supportive care, the outcome of children with acute lymphoblastic leukemia (ALL) has been improved dramatically.
  • In this study, treatment outcome of 82 childhood ALL patients in the hospital were analyzed, and ways for how to improve the EFS rate in childhood ALL were explored.
  • METHODS: Eighty-two patients with ALL were enrolled into the Nanfang ALL 99 protocol which derived from German BFM ALL 95 and Hong Kong-Singapore acute lymphoblastic leukemia 97 (HK-SG ALL 97).
  • RESULTS: From March 1999 to September 2003, 82 childhood ALL patients were treated with the Nanfang ALL 99 protocol and 78 (95.1%) patients attained complete remission (CR) in a median time of 33 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


94. Hughes AM, Lightfoot T, Simpson J, Ansell P, McKinney PA, Kinsey SE, Mitchell CD, Eden TO, Greaves M, Roman E, United Kingdom Childhood Cancer Study Investigators: Allergy and risk of childhood leukaemia: results from the UKCCS. Int J Cancer; 2007 Aug 15;121(4):819-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allergy and risk of childhood leukaemia: results from the UKCCS.
  • We investigated the relationship between childhood leukaemia and preceding history of allergy.
  • A nationwide case-control study of childhood cancers was conducted in the United Kingdom with population-based sampling of cases (n = 839) and controls (n = 1,337), matched on age, sex and region of residence.
  • For both total acute lymphoblastic leukaemia (ALL) and common-ALL/precursor B-cell ALL (c-ALL), a history of eczema was associated with a 30% significant reduction in risk: the odds ratios (OR) and 95% confidence intervals (CI) were 0.70 (0.51-0.97) and 0.68 (0.48-0.98), respectively.
  • No such patterns were seen either for asthma and ALL, or for any allergy and acute myeloid leukaemia.
  • Our finding of a reciprocal relationship between allergy and ALL in children is compatible with the hypothesis that a dysregulated immune response is a critical determinant of childhood ALL.
  • [MeSH-major] Hypersensitivity / epidemiology. Leukemia / epidemiology

  • MedlinePlus Health Information. consumer health - Allergy.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390373.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME, Melnick A, Brown P: Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood; 2010 Jun 10;115(23):4798-809
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
  • Cooperating leukemogenic events in MLL-rearranged (MLL-r) infant acute lymphoblastic leukemia (ALL) are largely unknown.
  • The HELP (HpaII tiny fragment enrichment by ligation-mediated polymerase chain reaction [PCR]) assay was used to examine genome-wide methylation of a cohort of MLL-r infant leukemia samples (n = 5), other common childhood ALLs (n = 5), and normals (n = 5).
  • In cell line treatment assays with the DNA methyltransferase inhibitor (DNMTi) decitabine, MLL-r (but not MLL wild-type cell lines) showed dose- and time-dependent cytotoxicity and re-expression of 4 of the 5 silenced genes.